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IN VIVO MEASUREMENT OF HUMAN BODY COMPOSITION
The work performed during this 6-month period.was concerned entirely with
completion of the laboratory analysis of the blood and urine samples collected
from the subjects of the 1973 NASA/Ames Female Bed-Rest Study. Details of our
participation in this study were given in the previous Semi-Annual Status
Report, No. 3.
Briefly, 12 female subjects resided in the NASA/Ames Human Research
Facility from 16 September to 22 October 1973. After a preliminary base-line
period of 2 weeks, 8 of the subjects remained continuously recumbent for
17 days and were designated the Bed-Rest Group. The other 4 subjects remained
ambulatory but were confined to the Facility throughout the study, and were
designated the Ambulatory Group. Both groups were studied for an additioAal
.6 days after the period of continuous recumbency for the Bed-Rest Group.
Table 1 lists the vital statistics of the 12 subjects at the start of the study.
In order to accomplish our measurements the subjects were arbitrarily
subdivided into 2 sections, each containing 4 members of the Bed-Rest Group
and 2 members of the Ambulatory Group. The measurement schedules for the
2 sections were staggered by a day, so that the subjects could be transported
to Berkeley on successive days for the tests conducted here. The Berkeley
measurements for each section were made on Day 7 before the Bed-Rest Group
started the continuous recumbency, on Day 17 of the recumbency, and on Day 6
after continuous recumbency of the Bed Rest Group was terminated. Thus, each
subject was studied on 3 occasions in Berkeley.
Body Weight. Table 2 gives the morning body-weight.values for each
subject in the 2 groups on Day 7 before the start of continuous recumbency of
the Bed-Rest Group, on Day 17 of recumbency of the Bed-Rest Group, and on
2Day 6 after continuous recumbency was concluded. The mean, standard devia-
tion, and standard error for each group on each of the 3 days are also shown.
The t-test was applied to these data to determine whether or not signifi-
cant differences existed between the various group means. Thus, the mean value
on Day 17 of recumbency was compared with the base-l ne mean obtained before
recumbency began. Similarly, the mean value on Day 6 after recumbency was
terminated was compared with the base-line mean. These comparisons were made'
for each of the 2 groups, and the probabilities that the pairs. of means
compared came from the same statistical population are shown in Table 2. If
the value of P was less than .05, the means were considered to differ signifi-
cantly. Comparison was also made between the normalized means for each of the
2 groups on Day 17 of recumbency, and on Day 6 of recovery, considering the
base-line value for each subject to represent 100%. The P values for these
comparisons are also given in Table 2.
It may be seen that in the case of body weight none of the P values
computed fell below 0.05. Hence, it can be concluded that in this group of
subjects there was no significant change in body weight, either as a result of
17 days of recumbency or as a result of the more general confinement conditions
under which the study was carried out.
Plasma Volume. A substantial decrease in plasma volume, amounting t6
10-15%, has come to be recognized as a characteristic response of male subjects
to continuous recumbency lasting a week or more. Table 3 gives the results of
the plasma volumes measured by dilution of T-1824 (Evans Blue) dye in the
present study.
It may be seen that on Day 17 of continuous recumbency, the Bed-Rest Group
exhibited a highly significant fall of 12.6% in their mean plasma volume,
3whereas the Ambulatory Group showed no significant change at this same time.
By Day 6 of recovery, the Bed-Rest Group plasma volume was apparently completely
restored. It should be noted that the comparison between the normalized means
for the 2 groups on Day 17 of recumbency also showed a highly significant
difference in the way in which the 2 groups responded to the experiment condi-
tions; whereas, on Day 6 of recovery there was no demonstrable difference
between the 2 groups.
It may be concluded, therefore, that plasma volume was significantly
reduced on Day 17 in the Bed-Rest Group, but not in the Ambulatory Group, and
that this was the result of the continuous recumbency experienced by the former
group. It may also be concluded that the other experiment conditions had no
significant effect on plasma volume.
Hematology. Both venous hematocrit value and blood hemoglobin concentra-
tion were measured in these subjects, and the results are given in Tables 4
and 5. Unfortunately, a decision was made by NASA before the experiment to
eliminate the measurement of 51Cr red cell volume from our protocol in the
interests of avoiding the 5 millirad radiation dose to the subjects, which is.
associated with the procedure. Therefore, changes in this important parameter
could not be followed.
As may be seen in Tables 4 and 5, both the venous hematocrit value and the
blood hemoglobin level fell progressively in both groups throughout the course
of the study, reaching values of 85 to 88% of base line for both parameters
by Day 6 of the post-recumbency period. This is in contrast with results from
previous bed-rest studies, which show that venous hematocrit values and blood
hemoglobin levels are characteristically elevated during periods of continuous
recumbency. It is regrettable that the red cell volume could not have been
measured to substantiate it, but a likely inference which can be drawn is that
both groups in the present study experienced a substantial decrease in total
circulating red blood cells. Whether this may have been the result of the
rather sizeable blood sampling that occurred during the total study, or a
consequence of the general conditions of the confinement in the Human Research
Facility cannot be stated with certainty. However, the former explanation
appears to be the more likely one at this time.
Body Water Compartments. As may be seen in Table 6, the mean value of
total body water content in both groups was lower on Day 17 of the recumbency
period than it was before recumbency began; however, despite the fact that the
mean decrease from the base value was greater in the Bed-Rest Group, the
difference achieved statistical significance only in the Ambulatory Group.
There was no significant difference between the normalized means of the two
groups on Day 17.
The extracellular fluid volume was measured as the bromide space, and the
results are given in Table 7. As may be seen, the extracellular volume tended
to be lower in the Bed-Rest Group on Day 17 of the recumbency period, but was
significantly elevated in the Ambulatory Group on the same day. Comparison of
the change in normalized means for the two groups on Day 17 revealed a signifi-
cant difference between them. There was no statistically significant difference
between the base values and the values measured on Day 6 of the post-recumbency
period in either group; likewise, there was no significant difference in the
change in normalized means between the two groups on that day.
The intracellular fluid volume was computed as the difference between total
body water (Table 6) and extracellular volume (Table 7), and the results are
shown in Table 8. Intracellular volume was significantly lower in the
Ambulatory Group on Day 17 of the recumbency period, and in both groups on
5Day 6 of the post-recumbency period. It also tended to be lower in the Bed-Rest
Group on Day 17 of the recumbency period, but the difference from the base value
did not attain statistical significance. There were no significant differences
between the normalized means for the two groups on either day.
As in the RGG Bed-Rest Study, there is strong indication in the water
compartment data that a net loss of water from the body occurs during prolonged
recumbency, and that the loss amounts to about 1 liter. However, the inherent
variance in the water-compartment measurement procedures themselves put the
statistics right at the edge of significance. There is the further indication
in these data from the Female Bed-Rest Study that water is lost from both the
extracellular and intracellular compartments, but further investigation is
needed to establish this conclusion firmly. The recommendation made in the
previous Status Report, that radioactive tritiated water rather than deuterated
water be used for total body water measurements, is reiterated. Use of T20 as
the tracer would materially reduce the procedural variance associated with
these measurements, and the enhanced accuracy should permit better assessment
of the body fluid changes associated with prolonged recumbency.
Body Potassium. Total body potassium content was measured by determining
the natural gamma radiation from 40K when the subject was placed in the whole-
body scintillation counter, and the results are shown in Table 9. It is
evident that the Bed-Rest Group lost an average of 3.3% of their total body
potassium by Day 17 of recumbency, whereas there was no significant change in
body potassium content of the Ambulatory Group during this period. The
normalized means for the two groups were also significantly different from
each other on Day 17. By Day 6 of the recovery period, the body potassium
content of the Bed-Rest Group had apparently been restored to the pre-recumbency
base-line values.
6It may be concluded that female subjects display a reduction in total body
potassium content after 2-3 weeks of continuous recumbency, but the decrease in
body potassium may be somewhat less in women than in men.
Plasma Electrolytes. Plasma levels of potassium, sodium, calcium, magnesium,
and chloride were measured during the study, and the results are given in Tables
10-14. Plasma potassium tended to fall in the Bed-Rest Group, as has been the
--case-in-male-bed--rest subjects-, but if anything-increas eds lightly in the
Ambulatory Group. Thus, the normalized means for the 2 groups on Day 17 of the
recumbency period were significantly different from each other. The entire
question of potassium balance of the body during prolonged recumbency remains
of interest.
Plasma sodium, magnesium, and chloride concentrations exhibited small, but
statistically significant elevations in both groups on Day 17 of the recumbency
period. Sodium levels had returned to base-line values by Day 6 of recovery in
both groups, but magnesium and chloride remained elevated in both groups at this
time. Plasma calcium concentration remained unchanged in both groups throughout
the study. The significance of these small, but apparently real, changes in
plasma electrolyte concentrations with respect to prolonged recumbency is not
clear at present, but may be related to the overall shifts in fluid and
electrolyte balance. In any case, these parameters are worthy of further study.
Plasma Proteins. Total plasma protein concentration did not change
significantly either in the Bed-Rest Group or in the Ambulatory Group, as may
be seen in Table 15. On the other hand, when the individual plasma protein
fractions were examined electrophoretically, as shown in Tables 16-18, several
significant differences emerged.
Plasma albumin concentration tended to be low in both groups on Day 17 of
7the recumbency period, but attained statistical significance only in the Bed-
Rest Group. The mean values for both groups seemed to have returned to base
line by Day 6 of the post-recumbency period. Comparison of the normalized means
on Day 17 of recumbency revealed no significant difference between the two groups.
In contrast, both the plasma globulins concentration and the plasma
fibrinogen concentration were elevated on Day 17 of the recumbency period in
both the Bed-Rest Group and the Ambulatory Group, as shown in Tables 17 and 18.
Only the plasma globulins concentration increase in the Ambulatory Group did
not attain statistical significance. Again, there were no significant differ-
ences between the normalized means of these parameters for the two groups on
Day 17. Also, by Day 6 of the post-recumbency period the mean values for both
parameters were indistinguishable from the base-line values.
As might be expected from the foregoing results, and as may be seen in
Table 19, the plasma albumin/globulin ratio was depressed on Day 17 of thel
recumbency period in both groups, although statistical significance was
attained only in the Bed-Rest Group. By Day 6 of the post-recumbency period
the albumin/globulin ratio had been restored to base line.
In general terms, it appears that while total plasma protein concentration
was unchanged on Day 17 of the recumbency period, a shift in composition had
occurred such that albumin concentration was reduced while the other major
fractions had increased proportionately. The reasons for this shift are not
clear, but may be related to the increased hemopoietic challenge occasioned by
the sizeable blood-sampling program involved in the study. It is also possible,
of course, that the changes may have been a consequence of the overall confine-
ment conditions experienced by both groups, although this would seem less
likely a possibility.
Closer examination of the plasma protein concentration shifts was made by
8computing the circulating quantities of total and individual fractions, as
presented in Tables 20-23. When circulating total plasma protein was examined
(Table 20), the interesting result emerged that on Day 17 of the recumbency
period a substantial and significant drop had occurred in the Bed-Rest Group,
while at the same time the Ambulatory Group was unchanged and, if anything,
was slightly elevated. This difference was clearly reflected by the highly
significant difference between the normalized means for the two groups on
Day 17. By Day 6 of the post-recumbency period, the circulating total plasma
protein of the Bed-Rest Group had returned to base line, and the difference
between the two groups had disappeared.
The decrease in total circulating plasma protein of the Bed-Rest Group was
probably a consequence of the substantial decrease in plasma volume in this
group noted earlier. It is of interest, and probably of physiological signifi-
cance, that the mean decrease in plasma volume measured on Day 17 of recumbency
in the Bed-Rest Group amounted to 12.6% (Table 3), while the mean decrease in
total circulating plasma protein in the same group on that day was 11.4%
(Table 20). Thus, prolonged recumbency results not only in a decrease in
plasma volume, but also in a concomitant decrease in total circulating plasma
protein.
As may be seen in Tables 21 and 22, the decrease of about 20 g in total
circulating plasma protein by Day 17 of recumbency in the Bed-Rest Group was
accounted for entirely by a comparable reduction in the quantity of circulating
albumin, while the quantity of circulating globulins was essentially unchanged.
Thus, the decrease in total circulating plasma protein during recumbency seems
to occur as the result of a specific decrease in the amount of albumin circulat-
ing in the vascular system.
9Inspection of the data in Table 23 for the quantity of circulating plasma
fibrinogen reveals another interesting change. By Day 17 of the recumbency
period, both the Bed-Rest Group and the Ambulatory Group displayed a substantial
and highly significant increase in circulating fibrinogen, which persisted into
Day 6 of the post-recumbency period although to a lesser extent. Furthermore,
the increase on Day 17 was significantly greater in the Ambulatory Group than
it was in the Bed-Rest Group. An explanation for this change is not apparent;
however, it may possibly be another manifestation of the hemopoietic challenge
consequent upon the sizeable blood sampling, as noted earlier.
The plasma concentrations of the individual globulin fractions were also
measured separately, and the results are given in Tables 24-27. Although the
concentration of each of the 4 globulin fractions was slightly elevated on
Day 17 of recumbency in the Bed-Rest Group, only the concentration of 6-globulin
was statistically significantly increased. No significant change from base
line was noted either in the Ambulatory Group on Day 17 of the recumbency
period, or in both groups on Day 6 of the post-recumbency period. When the
circulating quantities of the individual globulin fractions were computed as
shown in Tables 28-31, no changes were discernible during the study. Thus, it
may safely be concluded that prolonged recumbency had no effect on the plasma,
globulins.
Plasma Enzymes. A puzzling increase in plasma alkaline phosphatase
concentration was observed in both the Bed-Rest Group and the Ambulatory Group
on Day 17 of the recumbency period, and the increase persisted to Day 6 of the
post-recumbency period. The data are shown in Table 32. The increase was
moderately large and highly significant statistically. Plasma alkaline
phosphatase levels are thought to reflect osteoblast activity in the skeleton,
and in the previous RGG Bed-Rest Study with male subjects the levels were down
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after prolonged recumbency. Why these female subjects in both groups should
display elevated plasma alkaline phosphatase levels is totally unclear.
As may be seen in Table 33, both the Bed-Rest Group and.the Ambulatory
Group showed a small but statistically significant decrease in glutamate-
oxaloacetate transaminase levels on Day 17 of the recumbency period and on
Day 6 of the post-recumbency period. Glutamate-pyruvate plasma levels, shown
in Table 34, also showed a tendency to decline in both groups, reaching
statistical significance on Day 6 of the post-recumbency period. The physiolog-
ical import of these changes in plasma transaminase enzyme levels is once again
not readily apparent.
Plasma total lactate dehydrogenase concentration was significantly reduced
in both the Bed-Rest Group and the Ambulatory Group on Day 17 of the recumbency
period, as indicated in Table 35. There was a tendency for the mean values in
both groups to return toward base line by Day 6 of the post-recumbency period;
however, they were still significantly lower than base line at that time.
When the LDH isoenzymes were examined electrophoretically (Tables 36-40)
it was seen that the decrease in total LDH on Day 17 of the recumbency period
in both the Bed-Rest Group and the Ambulatory Group was accounted for almost
entirely by a large decrease in plasma concentration of the LDH-l fraction,
the isoenzyme associated primarily with heart muscle (Table 36). The other 4
isoenzymes either did not change at all, or in the case of LDH-3 actually
increased. Of particular interest is the fact that LDH-5, the isoenzyme
associated with skeletal muscle, showed no significant change in either group.
In general, these results are not dissimilar to the findings on the male
subjects of the RGG Bed-Rest Study, and further examination of the plasma LDH
enzyme system in future bed-rest studies appears to be warranted.
Urinary Constituents Excretion Rates. The values measured for 24 different
parameters on the 24-hour urine collections obtained during the study are given
in Tables 41-64. Overall perusal of the changes found, which may be done
conveniently from summary Table 65, reveals the startling fact that without
exception the individual urinary constituent values either decreased or did not
change significantly on Day 17 of the recumbency period for either the Bed-Rest
Group or the Ambulatory Group.
In searching for an explanation for this unexpected result, attention was
directed to the data in Table 55 for the urinary creatinine excretion rate.
Previous bed-rest studies have shown quite clearly that creatinine excretion
rate is relatively stable and unchanged during prolonged recumbency, as indeed
was found to be the case in the RGG Bed-Rest Study. In the latter study, the
coefficient of variation (S.D./Mean) hovered right around 10% for creatinine
excretion rates during the various phases.
In the present study, examination of Table 55 shows that while the
coefficient of variation for the base-line creatinine values was 9.8% in the
Bed-Rest Group and 9.1% for the Ambulatory Group, it rose substantially to
24.1% and 25.4%, respectively, on Day 17 of the recumbency period, and to
28.2% and 30.4%, respectively, on Day 6 of the post-recumbency period.
Closer inspection of the data in Table 55 reveals that the greatly increased
variances in creatinine excretion rate on Day 17 and Day 6 result from excep-
tionally low values for only some of the subjects. Furthermore, these large
deviations are not systematic.
In a similar vein, when Tables 41 and 42, which give the urine volume and
specific gravity data, are examined and compared with Table 55, the same large
variance is seen in the urine volume for the same subjects, but without a
corresponding large variance in the urine specific gravity which one would
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expect. The values for many of the urine constituents show comparable anomalies.
The conclusion which must regrettably be drawn, therefore, is that the
24-hour urine collections were incomplete for a number of the subjects of both
groups during Day 17 of the recumbency period, and during Day 6 of the post-
recumbency period. If this was indeed the case, it would not only explain the
tendency for so many of the mean values of the parameters to be lower than
base line during the experiment, but more seriously it precludes drawing
significant conclusions about the effect of prolonged recumbency on the
excretion rate of any of the urinary constituents measured.
As an alternative, the excretion rates of the various urinary constituents.
can be computed per unit creatinine excreted, instead of in absolute terms.
While the normal physiological variance in creatinine excretion rate artifactually
increases the true variance of constituent involved and while the missing frac-
tions of the 24-hour collections are not taken into account, at least this
approach should reveal any major changes in urine constituent excretion rate.
Accordingly, the data for appropriate urine constituents were recomputed in
terms of excretion per unit of urinary creatinine instead of excretion per
unit of time. The results are presented in Tables 66-83, and a summary of
the significant changes is given in Table 84. It is suggested that this summary
is more correct for the behavior of the urine constituents than is the summary
given in Table 65.
In general, it may be seen that the monovalent ions, chloride, sodium and
potassium (Tables 67-69) were statistically significantly reduced on Day 17 of
the recumbency period in the Bed-Rest Group. However, while statistical
significance was not achieved, there was a strong tendency for these parameters
to change in the same direction in the Ambulatory Group as well. There was
also a small, but significant, difference between the normalized means for
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potassium excretion per unit creatinine of the Bed-Rest Group and the Ambulatory
Group on Day 17, but this appeared to be a difference in degree of change and
was not interpreted as signifying a particular effect of prolonged recumbency.
No significant change in urinary Na/K ratio (Table 48) was observed. The i
overall impression is that the differences observed in these parameters may
have arisen from dietary differences. It is of interest that the total osmotic
activity of the urine (Table 66) was also depressed significantly on Day 17,
but this seems largely accounted for by the reduction primarily in sodium and
chloride ions.
In contrast, magnesium, calcium and phosphate excretion per unit creatinine
(Tables 70-72) all were elevated on Day 17 of the recumbency period in both the
Bed-Rest Group and the Ambulatory Group. Again, the changes achieved statis-
tical significance in the Bed-Rest Group but not quite in the Ambulatory Group.
Although these changes are in agreement with the earlier findings from the
NASA/Ames RGG Bed-Rest Study, and with other bed-rest studies, it must be
pointed out that there was no significat difference between the normalized
means for the Bed-Rest Group and the Ambulatory Group on Day 17. Also, as
noted earlier, the plasma alkaline phosphatase levels in both groups showed
an unexpected, and unexplained, increase. Thus, it is not possible to conclude
with certainty that these urine ion changes are a particular consequence of
prolonged recumbency. It is of some interest to note that the excretion of
magnesium and calcium had returned to base line by Day 6 of the post-recumbency
period, whereas phosphate excretion still tended to be elevated at that time.
These results are strongly reminiscent of the changes observed during the earlier
RGG Bed-Rest Study.
Urine urea excretion per unit creatinine (Table 75) was significantly lower
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in both the Bed-Rest Group and the Ambulatory Group, as was urine glucose
excretion per unit creatinine (Table 78). However, in neither case was there
a demonstrable difference between the normalized means for the two groups.
It is concluded, therefore, that these changes more likely represent dietary
variance than an effect of prolonged recumbency per se.
Urine citrate excretion per unit creatinine (Table 79) was significantly
elevated by about 55% in the Bed-Rest Group, both on Day 17 of the recumbency
period and on Day 6 of the post-recumbency period. It was elevated to the same
extent on both these days in the Ambulatory Group as well, but the difference
did not attain statistical significance in this group. On re-examination of
the RGG Bed-Rest Study urine citrate data (Table 50 of Status Report No. 3),
it emerges clearly that urinary citrate excretion rate tended to be about 40%
elevated both on Day 14 of bed rest and on Day 6 of recovery, and nearly
reached statistical significance. For the combined data of the Control Group
and RGG Group, the value of P on Day 14 of bed rest was 0.089, and on Day 6 of
recovery it was 0.053. Thus, it is concluded that prolonged recumbency may
involve a substantial increase in urinary citrate excretion rate, and that
this phenomenon deserves further study.
Urine norepinephrine excretion per unit creatinine (Table 82) was
significantly depressed on Day 17 of the recumbency period in the Bed-Rest
Group, but not in the Ambulatory Group. Furthermore, the difference between
the normalized means for the two groups on that day was nearly (P = 0.055)
statistically significant. Thus, it appears that prolonged recumbency may
result in a significant reduction in norepinephrine production. It is of
further interest to note that both groups displayed a significant elevation
over base line in norepinephrine excretion on Day 6 of the post-recumbency
period.
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Urine cyclic-AMP excretion per unit creatinine (Table 83) was significantly
elevated in the Ambulatory Group on Day 17 of the recumbency period, and
approached significant elevation (P = 0.098) in the Bed-Rest Group at that
time. This observation would seem to warrant further attention to urinary
cyclic-AMP measurements during prolonged recumbency studies.
Summary. In general, the 1973 NASA/Ames Female Bed-Rest Study has shown
that, for the parameters measured by this laboratory, the response of women to.
prolonged recumbency of 2-3 weeks duration is very similar to that displayed by
men. There were several minor differences between the results of the 1973
NASA/Ames RGG Study and those from the present study, but it is concluded that
most were probably the result of differences in experiment conditions between
the two studies rather than the result of a true sex difference in response to
prolonged recumbency.
Some of the key findings in the women after 17 days of continuous
recumbency were:
o A decrease in plasma volume of 12-13 per cent.
o A small decrease in total body water.
o A decrease in total body potassium of 3-4 per cent.
o A decrease in plasma potassium concentration of 4-5 per cent.
o A decrease in total circulating plasma protein, largely from
the circulating albumin, of 11-12 per cent.
o A decrease in urinary norepinephrine excretion rate of 27-28 per cent.
o A possible increase in urinary magnesium, calcium, and phosphate
excretion rates.
o A possible increase in urinary citrate excretion rate.
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A number of other parameters exhibited changes possibly related to the
effects of prolonged recumbency, but further investitation is needed to
verify such a conclusion. There seems to be little doubt concerning the
importance of conducting additional studies of this fundamental physiological
phenomenon.
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Table 1. Identification and vital statistics for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Surface
Age Height Weight Area
Subject - (yr) (cm) (kg) (m2 )
Bed-Rest Group
CAP 33 163 60.8 1.65
FRE 35 159 55.3 1.56
KEE 26 173 63.4 . 1.76
KUL 24 157 53.1. 1.52
PAR 32 163 58.2 1.62
SCH 25 157 50.4 1.49
VAN 23 157 53.0 1.52
ZIM 32 164 66.5 1.73
Mean 29 162 57.6 1.61
S.D. + 5 + 5 + 5.6 ± 0.10
Ambulatory Group
BEN 27 159 47.7 1.47
DEJ 29 170 61.5 1.71
PAC 27 170 64.1 1.74
QUE 25 164 51.0 1.54
Mean 27 166 56.1 1.62
S.D. + 2 + 5 ± 8.0 + 0.13
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Table 2. Body weight (kg) for the subjects of the 1973 NASA/Ames Female
Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value. Bed Rest Recovery 23-24 Sep .... 23-24 Sep
CAP 60.8 55.7 56.9 91.6 93.6
FRE 55.3 53.1 54.7 96.0 98.9
KEE 63.4 62.8 63.5 99.1 100.2
KUL 53.1 55.5 55.7 104.5 104.9
PAR 58.2 59.6 60.3 102.4 103.6
SCH 50.4 46.4 47.7 92.1 94.6
VAN 53.0 52.4 53.3 98.9 100.6
ZIM 66.5 65.5 65.8 98.5 98.9
Mean 57.6 56.4 57.2 97.9 99.4
S.D. ±5.6 ±6.1 L5.8 ±4.5 ±3.9
S.E. ±2.0 ±2.2 ±2.1 ±1.6 ±1.4
P Bed Rest = Base Value* 0.22
P Recovery = Base Value 0.67
Ambulatory Group
BEN 47.7 48.4 48.1 101.5 100.8
DEJ . 61.5 60.5 61.0 98.4 99.2
PAC 64.1 64.0 64.0 99.8 99.8
QUE 51.0 49.6 50.8 97.3 99.6
Mean 56.1 55.6 56.0 99.3 99.8
S.D. ±8.0 ±7.8 ±7.7 ±1.8 ±0.7
S.E. ±4.0 ±3.9 ±3.9 ±0.9 ±0.3
P 16-17 Oct = Base Value 0.41
P 21-22 Oct = Base Value 0.63
P Bed Rest = Ambulatory 0.48
P Recovery = Ambulatory 0.77
* Value of P <0.05 indicates a statistically significant difference
between the two populations compared.
Table 3. Plasma volume (liters) for the subjects of the 1973 NASA/Ames
Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject. Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 2.73 2.24 2.83 82.1 103.7
FRE 2.65 2.17 2.74 81.9 103.4
KEE 2.78 2.45 2.77 88.1 99.6
KUL 2.56 . 2.33 2.56 91.0 100.0
PAR 2.89 2.47 2.90 85.5 100.3
SCH 2.30 2.00 2.31 87.0 100.4
VAN 2.28 2.06 2.35 90.4 103.1
ZIM 2.80 . 2.60 3.02 92.9 107.9
Mean 2.62 2.29 2.68 87.4 102.3
S.D. ±0.23 ±0.21 ±0.26 ±4.0 ±2.8
S.E. ±0.08 ±0.07 ±0.09 ±1.4 ±1.0
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value 0.063
Ambulatory Group
BEN 2.32 2.56 2.82 . 110.3 121.6
DEJ 2.74 2.80 2.82 102.2 . 102.9
PAC 2.63 2.71 2.76 103.0 104.9
QUE 2.61 2.68 2.72 102.7 104.2
Mean 2.58 2.69 2.78 104.6 108.4
S.D. .0.18 ±0.10 ±0.05 .3.8 ±8.8
S.E. ±0.09 ±0.05 ±0.02 . ±1.9 ±4.4
P 16-17 Oct = Base Value 0.083
P 21-22 Oct = Base Value 0.14
P Bed Rest = Ambulatory <0.001*'
P Recovery = Ambulatory 0.21
* Value of P <0.05 indicates a statistically significant difference
between the two populations compared.
20
Table 4. Venous hematocrit value (%) for the subjects of the 1973
NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 40.4 41.6 33.8 103.0 83.7
FRE 42.9 40.1 34.7 93.5 80.9
KEE 43.8 39.4 35.8 90.0 81.7
KUL 40.7 37.4 32.1 91.9 78.9
PAR 39.9 39.6 37.2 99.2 93.2
SCH 40.8 39.0 36.5 95.6 89.5
VAN 38.9 34.4 32.1 88.4 82.5
ZIM 40.6 38.4 34.7 94.6 85.5
Mean 41.0 38.7 34.6 94.5 84.5
S.D. ±1.6 ±2.1 ±1.9 ±4.8 ±4.8
S.E. ±0.6 ±0.8 *0.7 ±1.7 ±1.7
P Bed Rest = Base Value* 0.015*
P Recovery = Base Value <0.001*
Ambulatory Group
BEN 40.0 36.2 32.0 90.5 80.0
DEJ 39.5 36.2 34.6 91.6 87.6
PAC 42.0 37.5 35.9 89.3 85.5
QUE 35.5 33.3 32.0 93.8 90.1
Mean 39.3 35.8 33.6 91.3 85.8
S.D. *2.7 ±1.8 *2.0 ±1.9 *4.3
S.E. *1.4 ±0.9 ±1.0 ±1.0 ±2.1
P 16-17 Oct = Base Value 0.008*
P 21-22 Oct = Base Value 0.010*
P Bed Rest = Ambulatory 0.14
P Recovery = Ambulatory 0.64
* Value of P <0.05 indicates a statistically significant difference
between the two populations compared.
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Table 5. Blood hemoglobin concentration (g/100 ml) for the subjects of
' the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value . Bed Rest Recovery . 23-24 Sep 23-24 Sep
CAP 13.9 14.5 12.1 104.3 87.1
FRE 14.4 13.9 12.3 96.5 85.4
KEE 15.3 13.9 13.1 90.8 85.6
KUL 14.4 13.8 12.5 95.8 86.8
PAR 13.8 14.1 13.3 102.2 96.'4
SCH 14.8 14.3 13.1 96.6 88.5
VAN 13.8 12.3 11.8 89.1 85.5
ZIM 13.7 13.8 12.6 100.7 92.0
Mean 14.3 13.8 12.6 97.0 88.4
S.D. ±0.6 ±0.7 ±0.5 ±5.3 ±3.9
S.E. ±0.2 ±0.2 ±0.2 ±1.9 ±1.4
P Bed Rest = Base Value* 0.15
P Recovery = Base Value <0.001*
Ambulatory Group
BEN 14.0 12.2 11.2 87.1 80.0
DEJ 14.1 12.6 13.0 89.4 92.2
PAC 15.1 13.6 12.9 90.1 85.4
QUE 12.4 12.6 11.8 101.6 95.2
Mean 13.9 12.8 12.2 92.1 88.2
S.D. ±1.1 ±0.6 ±0.9 ±6.5 ±6.8
S.E. ±0.6 ±0.3 ±0.4 ±3.2 ±3.4
P 16-17 Oct = Base Value 0.090
P 21-22 Oct = Base Value 0.047*
P Bed Rest = Ambulatory 0.22
P Recovery = Ambulatory 0.96
* Value of P <0.05 indicates a statistically significant difference
between the two populations compared.
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Table 6. Body water values (liters) for the subjects of the 1973
NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed.Rest Recovery 23-24 Sep 23-24 Sep
CAP 32.4 28.1 29.6 86.7 9 .4
FRE 30.4 28.4 29.6 93.4 97. 4
KEE 33.4 33.2 34.3 99.4 102.7
KUL 30.7 32.3 31.8 105.2 103.6
PAR 32.4 33.2 33.2 102.5 102.5
SCH 29.7 26.6 27.7 89.6 93.3
VAN 28.0 27,2 28.1 97.1 100.4
ZIM 36.0 36.1 36.7 100.3 101.9
Mean 31.6 30.6 31.4 96.8 99.2
S.D. ±2.5 ±3.5 ±3.2 ±6.4 +4.6
S.E. ±0.9 ±1.2 ±1.1 ±2.3 ±1.6
P Bed Rest = Base Value* 0.21
P Recovery = Base Value 0.65
Ambulatory Group
BEN 30.6, 30.1 29.9 98.4 97.7
DEJ 32.7 32.4 33.2 99.1 101.5
PAC 34.4 33.9 33.4 98.5 97.1
QUE 32.1 31.5 31.9 98.1 99.4
Mean 32.5 32.0 32.1 98.5 98.9
S.D. ±1.6 ±1.6 ±1.6 ±0.4 ±2.0
S.E. ±0.8 ±0.8 ±0.8 ±0.2 ±1.0
P 16-17 Oct = Base Value 0.005*
P 21-22 Oct = Base Value 0.36
P Bed Rest = Ambulatory 0.61
P Recovery = Ambulatory 0.93
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 7. Extracellular water values (liters) for the subjects of the 1973
NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 17.2 15.7 17.3 91.3 100.6
FRE 16.7 15.4 16.9 92.2 101.2
KEE 17.8 17.4 19.5 97..8 109.6
KUL 17.3 17.7 17.4 102.3 100.6
PAR 17.4 18.1 21.4 104.0 123.0
SCH 15.0 14.7 15.1 98.0 100.7
VAN 14.7 13.8 14.3 93.9 97.3
ZIM 19.3 19.7 22.4 102.1 116.1
Mean 16.9 16.6 18.0 97.7 106.1
S.D. ±1.5 ±2.0 ±2.9 ±4.9 ±9.2
S.E. ±0.5 ±0.7 ±1.0 ±1.7 +3.2
P Bed Rest = Base Value* 0.25
P Recovery = Base Value 0.097
Ambulatory Control Group
BEN 16.4 17.5 16.7 106.7 101.8
DEJ 16.9 17.3 18.2 102.4 107.7
PAC 17.2 18.0 17.3 104.7 100.6
QUE 17.3 18.0 19.6 104.0 113.3
Mean 17.0 17.7 18.0 104.4 105.8
S.D. ±0.4 ±0.4 ±1.3 ±1.8 ±5.9
S.E. ±0.2 ±0.2 ±0.6 ±0.9 ±2.9
P 16-17 Oct = Base Value 0.014*
P 21-22 Oct = Base Value 0.14
P Bed Rest = Control 0.025*
P Recovery = Control 0.96
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 8. Intracellular water values Cliters) for the subjects of the 1973
NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24.Sep 23-24 Sep
CAP 15.2 12.4 12.3 81.6 80.9
FRE 13.7 13.0 12.7 94.9 92.7
KEE 15.6 15.8 14.8 101.3 94.9
KUL 13.4 14.6 14.4 109.0 107.5
PAR 15.0 15.1 11.8 100.7 78.7
SCH 14.7 11.9 12.6 81.0 85.7
VAN 13.3 13.4 13.8 100.8 103.8
ZIM 16.7 16.4 14.3 98.2 85.6
Mean 14.7 14.1 13.3 95.9 91.2
S.D. ±1.2 ±1.6 ±1.1 ±9.9 ±10.4
S.E. ±0.4 ±0.6 ±0.4 ±3.5 + 3.7
P Bed Rest = Base Value* 0.26
P Recovery = Base Value 0.042*
Ambulatory Control Group
BEN 14.2 12.6 13..2 88.7 93.0
DEJ 15.8 15.1 15.0 95.6 94.9
PAC 17.2 15.9 16.1 92.4 93.6
QUE 14.8 13.5 12.3 91.2 83.1
Mean 15.5 14.3 14.2 92.0 91.2
S.D. ±1.3 ±1.5 ±1.7 ±2.9 ±5.4
S.E. ±0.7 ±0.7 ±0.9 ±1.4 ±2.7
P 16-17 Oct = Base Value 0.007*
P 21-22 Oct = Base Value 0.040*
P Bed Rest Control 0.46
P Recovery = Control 0.99
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 9. Body potassium content (eq) for the subjects of the 1973 NASA/Ames
Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17' Day 6 16-17 Oct 21-22 Oct
Subject. Base Valuie . Bed Rest Recovery . 23-24 Sep 23-24 Sep
CAP 3.06 2.90 2.99 94.8 97.7
FRE 3.11 2.97 3.04 95.5 97.7
KEE 2.97 2.81 2.83 94.6 95.3
KUL 3.05 2.97 3.02 97.4 99.0
PAR 2.97 2.95 3.07 99.3 103.4
SCH 3.25 . 3.12 3.20 96.0 98.5
VAN 2.61 2.49 2.55 95.4 97.7
ZIM 3.06 3.07 3.17 100.3 103.6
Mean 3.01 2.91 2.98 96.7 99.1
S.D. ±0.18 ±0.19 ±0.21 ±2.1 ±2.9
S.E. ±0.07 ±0.07 *0.07 ±0.8 ±1.0
P Bed Rest = Base Value* 0.006*
P Recovery = Base Value 0.42
Ambulatory Group
BEN 3.43 3.36 3.37 98.0 98.3
DEJ 2.98 3.01 2.97 101.0 99.7
PAC 3.09 3.14 3.18 101.6 102.9
QUE 3.04 2.99 3.01 98.4 99.0
Mean 3.23 3.12 3.13 99.8 100.0
S.D. ±0.20 ±0.17 ±0.18 ±1.8 ±2.0
S.E. ±0.10 ±0.09 ±0.09 +0.9 ±1.0
P 16-17 Oct = Base Value 0.76
P 21-22 Oct = Base Value 0.94
P Bed Rest = Ambulatory 0.028*
P Recovery = Ambulatory 0.57
* Value of P <0.05 indicates a statistically significant difference
between the two populations compared.
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Table 1G. Plasma potassium concentration (meq/liter) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value. Bed Rest Recovery 23-24 Sep .23-24 Sep
CAP 4.42 4.18 3.95 94.6 89.4
FRE 4.23 3.94 3.60 93.1 85.1
KEE 4.81 4.52 4.70 94.0 97.7
KUL 4.14 4.38 4.30 105.8 103.9
PAR 4.81 4.14 3.85 86.1 80.0
SCH 4.33 4.33 4.10 100.0 94.7
VAN 4.23 4.04 3.65 95.5 86.3
ZIM 4.71 4.42 4.30 93.8 91.:3
Mean 4.46 4.24 4.06 95.4 91.1
S.D. t0.28 ±0.20 t0.37 L5.7 ±7.6
S.E. ±0.10 ±0.07 ±0.13 ±2.0 ±2.7
P Bed Rest = Base Value* 0.053
P Recovery = Base Value 0.014*
Ambulatory Group
BEN 4.14 4.14 4.00 100.0 96.6
DEJ 4.23 4.38 4.15 103.5 98.1
PAC 4.04 4.33 3.95 107.2 97.8
QUE 4.04 4.47 4.15 110.6 102.7
Mean 4.11 4.33 4.06 105.3 98.8
S.D. 20.09 ±0.14 ±0.10 ±4.6 t2.7
S.E. ±0.05 ±0.07 ±0.05 ±2.3 ±1.3
P 16-17 Oct = Base Value 0.10
P 21-22 Oct = Base Value 0.43
P Bed Rest = Ambulatory, 0.014*
P Recovery = Ambulatory 0.085
* Value of P <0.05 indicates a statistically significant difference
between the two populations compared.
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Table 11. Plasma sodium concentration (meq/liter) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 138 147 144 106.5 104.3
FRE 137 149 137 108.8 100.0
KEE 136 147 141 108.1 103.7
KUL 138 152 137 110.1 99.3
PAR 138 145 141 105.1 102.2
SCH 136 140 132 102.9 97.1
VAN 137 152 132 110.9 96.4
ZIM 138 152 137 110.1 99.3
Mean 137 148 138 107.8 100.3
S.D. + 1 ± 4 ± 4 ± 2.8 ± 2.9
S.E. + 1 ± 1 ± 2 ± 1.0 ± 1.0
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value 0.80
Ambulatory Group
BEN 134 147 134 109.7 100.0
DEJ 136 154 134 113.2 98.5
PAC 141 152 139 107.8 98.6
QUE 134 147 130 109.7 97.0
Mean 136 150 134 110.1 98.5
S.D. + 3 - 4 + 4 ± 2.3 ± 1.2
S.E. 2 2 + 2 - 1.1 + 0.6
P 16-17 Oct = Base Value 0.003*
P 21-22 Oct = Base Value 0.092
P Bed Rest = Ambulatory 0.19
P Recovery = Ambulatory 0.28
SValue of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 12. Plasma calcium concentration (meq/liter) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value .. Bed.Rest Recovery. 23-24 Sep . 23-24 Sep
CAP 4.20 4.39 4.25 104.5 101.2
FRE 4.45 4.39 4.20 98.7 94.4
KEE 4.55 4.39 4.35 96.5 95.6
KUL 4.45 4.39 4.30 98.7 96.6
PAR 4.50 4.55 4.40 101.1 97.8
SCH 4.35 4.39 4.50 100.9 103.4
VAN 4.25 4,55 4.30 107.1 101.2
ZIM 4.35 4.22 4.35 97.0 100.0
Mean 4.39 4.41 4.33 100.6 98.8
S.D. ±0.12 ±0.11 ±0.09 ±3.7 ±3.2
S.E. ±0.04 ±0.04 ±0.03 ±1.3 ±1.11
P Bed Rest = Base Value* 0.72
P Recovery = Base Value 0.29
Ambulatory Group
BEN 4.35 4.56 4.25 104.8 97.7
DEJ 4.20 . 4.22 4.20 100.5 100.0
PAC 4.50 4.39 4.45 97.6. 98.9
QUE 4.15 4.22 4.30 101.7 103..6
Mean 4.30 4.35 4.30 101.2 100.1
S.D. ±0.16 ±0.16 ±0.11 ±3.0 +2.5
S.E. ±0.08 ±0.08 ±0.05 ±1.5 +1.3
P 16-17 Oct = Base Value 0.52
P 21-22 Oct = Base Value 1.00
P Bed Rest = Ambulatory 0.79
P Recovery = Ambulatory 0.50
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 13. Plasma magnesium concentration (meq/liter) for the subjects of the
1973 NASA/Ames Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 1.54 1.50 1.56 97.4 101.3
FRE 1.54 1.65 1.60 107.1 103.9
KEE 1.41 1.68 1.64 119.1 116.3
KUL 1.38 1.62 1.46 117.4 105.8
PAR 1.41 1.5Q 1.60 106.4 113.5
SCH 1.41 1.56 1.50 110.6 106.4
VAN 1.51 1.68 1.72 111.3 113.9
ZIM 1.41 1.56 1.56 110.6 110.6
Mean 1.45 1.59 1.58 110.0 109.0
S.D. ±0.07 ±Q0.07 ±0.08 ± 6.8 + 5.4
S.E. ±0.02 ±0.03 ±0.03 ± 2.4 + 1.9
P Bed Rest = Base Value* 0.04*
P Recovery = Base Value 0.002*
Ambulatory Group
BEN 1.49 1.56 1.56 104.7 104.7
DEJ 1.51 1.62 1.58 107.3 104.6
PAC 1.44 1.74 1.62 120.8 112.5
QUE 1.45 1.62 1.66 111.7 114.5
Mean 1.47 1.63 1.60 111.1 109.1
S.D. ±0.03 ±0.08 ±0.04 ± 7.1 + 5.2
S.E. ±0.02 ±0.04 ±0.02 ± 3.5 + 2.6
P 16-17 Oct = Base Value 0.048*
P 21-22 Oct = Base Value 0.036*
P Bed Rest = Ambulatory 0.79
P Recovery = Ambulatory 0.97
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 14. Plasma chloride concentration Cmeq/liter) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed.Rest..... Recovery. 23-24 Sep 23-24 Sep
CAP 104.3 105.5 107.5 101.2 103.1
FRE 99.0 104.8 105.8 105.9 106.9
KEE 103.8 108.1 108.0 104.1 104.0
KUL 100.3 105.0 105.6 104.7 105.3
PAR 104.0 104.8 106.2 100.8 102.1
SCH 103.0 105.9 104.9 102.8 101.8
VAN 104.3 107.0 107.2 102.6 102.8
ZIM 104.0 106.8 105.3 102.7 101.3
Mean 102.8 106.0 106.3 103.1 103.4
S.D. ± 2.0 ± 1.2 ± 1.1 + 1.7 ± 1.9
S.E. ± 0.7 ± 0.4 ± 0.4 + 0.6 ± 0.7
P Bed Rest = Base Value* 0.001*
P Recovery = Base Value 0.001*
Ambulatory Group
BEN 100.5 103.5 105.0 103.0 104.5
DEJ 103.8 106.7 105.7 102.8 101.8
PAC 102.4 107.8 108.8 105.3 106.3
QUE 103.6 106.7 106.4 103.0 102.7
Mean 102.6 106.2 106.5 103.5 103.8
S.D. ± 1.5 .± 1.9 ± 1.7 ± 1.2 ± 2.0
S.E. - 0.8 ± 0.9 ± 0.8 + 0.6 ± 1.0
P 16-17 Oct = Base Value 0.009*
P 21-22 Oct = Base Value 0.029*
P Bed Rest = Ambulatory 0.67
P Recovery = Ambulatory 0.74
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
31
Table 15. Plasma protein concentration Cg/100 ml) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed.Rest Recovery 23-24 Sep 23-24 Sep
CAP 6.26 6.58 6.12 105.1 97.8
FRE 7.31 7.05 6.74 96.4 92.2
KEE 6.97 6.58 6.31 94.4 90..5
KUL 6.72 6.58 6.01 97.9 89.4
PAR 6.38 6.55 6.56 102.7 102.8
SCH 6.35 7.05 7.01 111.0 110.4
VAN 6.67 6.55 6.71 98.2 100.6
ZIM 5.93 6.28 5.88 105.9 99.2
Mean 6.57 6.65 6.42 101.5 97.9
S.D. ±0.44 ±0.26 ±0.40 + 5.7 ± 7.1
S.E. ±0.15 ±0.09 ±0.14 + 2.0 ± 2.5
P Bed Rest = Base Value* 0.57
P Recovery = Base Value 0.38
Ambulatory Group
BEN 7.10 6.70 6.41 94.4 90.3
DEJ 6.58 6.60 6.34 100.3 96.4
PAC 6.49 6.62 6.44 102.0 99.2
QUE 6.38 7.15 6.81 112.1 106.7
Mean 6.64 6.77 6.50 102.2 98.2
S.D. ±0.32 ±0.26 ±0.21 ± 7.4 ± 6.8
S.E. ±0.16 ±0.13 ±0.11 + 3.7 ± 3.4
P 16-17 Oct = Base Value 0.63
P 21-22 Oct = Base Value 0.60
P Bed Rest = Ambulatory 0.85
P Recovery = Ambulatory 0.95
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 16. Plasma albumin concentration (g/100 ml) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 3.82 3.51 3.29 91.9 86.1
FRE 4.03 3.49 3.84 86.6 95.3
KEE 3.81 3.41 3.48 89.5 91.3
KUL 4.25 3.50 3.32 82.4 78.1
PAR 4.06 3.41 4.05 84.0 99.8
SCH 3.66 3.62 4.24 98.9 115.8
VAN 3.67 3.44 3.93 93.7 107.1
ZIM 3.59 3.30 3.46 91.9 96.4
Mean 3.86 3.46 3.70 89.9 96.2
S.D. ±0.23 ±0.09 ±0.36 + 5.4 ±11.8
S.E. ±0.08 ±0.03 ±0.13 + 1.9 _ 4.2
P Bed Rest = Base Value* 0.004*
P Recovery = Base Value 0.36
Ambulatory Group
BEN 3.70 3.32 3.54 89.7 95.7
DEJ 3.77 3.52 3.61 93.4 95.8
PAC 3.98 3.68 4.15 92.5 104.3
QUE 3.72 3.84 4.01 103.2 107.8
Mean 3.79 3.59 3.83 94.7 100.9
S.D. ±0.13 ±0.22 ±0.30 + 5.9 ± 6.1
S.E. ±0.06 ±0.11 ±0.15 ± 2.9 ± 3.1
P 16-17 Oct = Base Value 0.17
P 21-22 Oct = Base Value 0.78
P Bed Rest = Ambulatory 0.19
P Recovery = Control 0.48
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
33
Table 17. Plasma globulins concentration (g/100 ml) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 2.00 2.44 2.38 122.0 119.0
FRE 2.79 2.81 2.44 100.7 87.5
KEE 2.63 2.53 2.27 96.2 86.3
KUL .2.03 2.36 2.16 116.3 106.4
PAR 1.92 2.39 1.98 124.5 103.1
SCH 2.26 2.68 2.31 118.6 102.2
VAN 2.47 2.32 2.25 93.9 91.1
ZIM 1.84 2.28 1.93 123.9 104.9
Mean 2.24 2.48 2.22 112.0 100.1
S.D. ±0.35 ±0.19 ±0.18 +12.9 ±11.1
S.E. ±0.12 ±0.07 ±0.06 + 4.6 + 3.9
P Bed Rest = Base Value* 0.044*
P Recovery = Base Value 0.77
Ambulatory Group
BEN 2.81 2.55 2.20 90.7 78.3
DEJ 2.39 2.40 2.21 100.4 92.5
PAC 2.22 2.42 2.01 109.0 90.5
QUE 2.28 2.66 2.40 116.7 105.3
Mean 2.42 2.51 2.20 104.2 91.7
S.D. ±0.27 ±0.12 ±0.16 ±11.2 ±11.1
S.E. ±0.13 ±0.06 ±0.08 ± 5.6 + 5.5
P 16-17 Oct = Base Value 0.59
P 21-22 Oct = Base Value 0.24
P Bed Rest = Ambulatory 0.33
P Recovery = Ambulatory 0.25
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 18. Plasma fibrinogen concentration (g/100 ml) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest GroWp
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 0.44 0.63 0.45 143.2 102.31
FRE 0.49 0.75 0.46 153.1 93.9
KEE 0.53 0.64 0.56 120.8 105.7
KUL 0.44 0.72 0.53 163.6 120.5
PAR 0.40 0.75 0.53 187.5 132.5
SCH 0.43 0.75 0.46 174.4 107.0
VAN 0.53 0.79 0.53 149.1 100.0
ZIM 0.50 0.70 0.49 140.0 98.0
Mean 0.47 0.72 0.50 154.0 107.5
S.D. ±0.05 ±0.06 ±0.04 ±20.9 ±12.9
S.E. ±0.02 ±0.02 ±0.01 + 7.4 ± 4.5
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value 0.15
Ambulatory Group
BEN 0.59 0.83 0.67 140.7 113.6
DEJ 0.42 0.68 0.52 161.9 123.8
PAC 0.29 0.52 0.28 179.3 96.6
QUE 0.38 0.65 0.40 171.1 105.3
Mean 0.42 0.67 0.47 163.3 109.8
S.D. ±0.13 ±0.13 ±0.17 ±16.6 ±11.6
S.E. ±0.06 ±0.06 ±0.08 ± 8.3 ± 5.8
P 16-17 Oct Base Value <0.001*
P 21-22 Oct = Base Value 0.17
P Bed Rest = Ambulatory 0.46
P Recovery = Ambulatory 0.77
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 19. Plasma albumin/globulin ratio for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 1.91 1.44 1.38 75.4 72.3
FRE 1.44 1.24 1.57 86.1 109.0
KEE 1.45 1.35 1.53 93.1 105.5
KUL 2.09 1.48 1.54 70.8 73.7
PAR 2.11 1.43 2.05 67.8 97.2
SCH 1.62 1.35 1.84 83.3 113.6
VAN 1.49 1.48 1.75 99.3 117.4
ZIM 1.95 1.45 1.79 74.4 91.8
Mean 1.76 1.40 1.68 81.3 97.6
S.D. ±0.29 ±0.08 ±0.22 +11.1 ±17.3
S.E. ±0.10 ±0.03 ±0.08 + 3.9 + 6.1
P Bed Rest = Base Value* 0.007*
P Recovery = Base Value 0.52
Ambulatory Group
BEN 1.32 1.30 1.61 98.5 122.0
DEJ 1.58 1.47 1.63 93.0 103.2
PAC 1.79 1.52 2.06 84.9 115.1
QUE 1.63 1.44 1.67 88.3 102.5
Mean 1.58 1.43 1.74 91.2 110.7
S.D. ±0.20 ±0.09 ±0.21 + 5.9 ± 9.5
S.E. ±0.10 ±0.05 ±0.11 + 3.0 ± 4.7
P 16-17 Oct = Base Value 0.076
P 21-22 Oct = Base Value 0.098
P Bed Rest = Ambulatory 0.14
P Recovery = Ambulatory 0.19
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 20. Circulating plasma protein (g) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 171 147 173 86.0 101.2
FRE 194 153 185 78.9 95.4
KEE 194 161 175 83.0 90.2
KUL 172 153 154 89.0 89.5
PAR 184 162 190 88.0 103.3
SCH 146 141 162 96.6 111.0
VAN 152 135 158 88.8 103.9
ZIM 166 163 178 98.2 107.2
Mean 172 152 172 88.6 100.2
S.D. ±18 ±10 ±13 ±6.4 ±7.8
S.E. 6 4 5 ±2.3 ±2.8
P Bed Rest = Base Value* 0.005*
P Recovery = Base Value 0.92
Ambulatory Group
BEN 165 172 181 104.2 110.0
DEJ 180 185 179 102.8 99.4
PAC 171 179 178 104.7 104.1
QUE 167 192 185 115.0 110.8
Mean 171 182 181 106.7 106.1
S.D. ±7 ±9 ±3 ±5.6 ±5.4
S.E. ±3 ±4 ±2 ±2.8 ±2.7
P 16-17 Oct = Base Value 0.095
P 21-22 Oct = Base Value 0.11
P Bed Rest = Ambulatory <0.001*
P Recovery = Ambulatory 0.21
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 21. Circulating plasma albumin (g) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 104 79 93 76.0 89.4
FRE 107 76 105 71.0 98.1
KEE 1106 84 96 79.2 90.6
KUL 109 82 85 75.2 78.0
PAR 117 84 117 71.8 100.0
SCH 84 72 98 85.7 116.7
VAN 84 71 92 84.5 109.5
ZIM 101 86 104 85.1 103.0
Mean 102 79 99 78.6 98.2
S.D. +12 ±6 ±10 + 6.0 ±12.2
S.E. 4 ±2 3 2.1 4.3
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value 0.54
Ambulatory Group
BEN 86 85 100 98.8 116.3
DEJ 103 99 102 96.1 99.0
PAC 105 100 115 95.2 109.5
QUE 97 103 109 106.2 112.4
Mean 98 97 107 99.1 109.3
S.D. + 9 ± 8 ± 7 ± 5.0 + 7.4
S.E. + 4 ± 4 ± 3 ± 2.5 ± 3.7
P 16-17 Oct = Base Value 0.71
P 21-22 Oct = Base Value 0.084
P Bed Rest = Ambulatory <0.001*
P Recovery = Ambulatory 0.14
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 22. Circulating plasma globulins (g) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 54.6 54.7 67.4 100.2 123.4
FRE 73.9 61.0 66.9 82.5 90.5
KEE 73.1 62.0 62.9 84.8 86.0
KUL 52.0 55.0 55.3 105.8 106.3
PAR 55.5 59.0 57.4 106.3 103.4
SCH 52.0 53.6 53.4 103.1 102.7
VAN 56.3 47.8 52.9 84.9 94.0
ZIM 51.5 59.3 58.3 115.1 113.2
Mean 58.6 56.6 59.3 97.8 102.4
S.D. ±9.4 ±4.7 ±5.8 +12.2 ±12.3
S.E. ±3.3 ±1.7 ±2.0 + 4.3 ± 4.3
P Bed Rest = Base Value* 0.47
P Recovery = Base Value 0.80
Ambulatory Group
BEN 65.2 65.3 62.0 100.2 95.1
DEJ 65.5 67.2 62.3 102.6 95.1
PAC 58.4 65.6 55.5 112.3 95.0
QUE 59.5 71.3 65.3 119.8 109.7
Mean . 62.2 67.4 61.3 108.7 98.7
S.D. ±3.7 ±2.8 ±4.1 + 9.0 + 7.3
S.E. ±1.9 ±1.4 ±2.1 + 4.5 + 3.7
P 16-17 Oct = Base Value 0.16
P 21-22 Oct = Base Value 0.72
P Bed Rest = Ambulatory 0.16
P Recovery = Ambulatory 0.59
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 23. Circulating plasma fibrinogen (g) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 12.0 14.1 12.7 117.5 105.8
FRE 13.0 16.3 12.6 125.4 96.9
KEE 14.7 15.7 15.5 106.8 105.4
KUL 11.3 16.8 13.6 148.7 120.4
PAR 11.6 18.5 15.4 159.5 132.8
SCH 9.9 15.0 10.6 151.5 107.1
VAN 12.1 16.3 12.5 134.7 103.3
ZIM 14.0 18.2 14.8 130.0 105.7
Mean 12.3 16.4 13.5 134.3 109.7
S.D. ±1.5 ±1.5 ±1.7 ±18.0 ±11.4
S.E. ±0.5 ±0.5 ±0.6 + 6.4 ± 4.0 i
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value 0.045*
Ambulatory Group
BEN 13.7 21.2 18.9 154.7 138.0
DEJ 11.5 19.0 14.7 165.2 127.8
PAC 7.6 14.1 7.7 185.5 101.3
QUE 9.9 17.4 10.9 175.8 110.1
Mean 10.7 17.9 13.1 170.3 119.3
S.D. ±2.6 ±3.0 ±4.8 ±13.3 ±16.6
S.E. ±1.3 ±1.5 ±2.4 ± 6.6 + 8.3
P 16-17 Oct = Base Value <0.001*
P 21-22 Oct = Base Value 0.14
P Bed Rest = Ambulatory 0.008*
P Recovery = Ambulatory 0.26
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 24. Plasma a-l-globulin concentration (g/lO0 ml) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 0o14 0.20 0.23 142.9 164.3
FRE 0.20 0.24 0.25 120.0 125.0
KEE 0.22 0.18 0.23 81.8 104.5
KUL 0.16 0.21 0.16 131.3 100.0
PAR 0.18 0.19 0.18 105.6 100.0
SCH 0.24 0.23 0.23 95.8 95.8
VAN 0.24 0.22 0.23 91.7 95.8
ZIM 0.11 0.21 0.17 190.9 154.5
Mean 0.19 0.21 0.21 120.0 117.5
S.D. ±0.05 ±0.02 ±0.03 +35.3 ±27.6
S.E. ±0.02 ±0.01 ±0.01 ±12.5 + 9.8
P Bed Rest = Base Value* 0.20
P Recovery = Base Value 0.12
Ambulatory Group
BEN 0.21 0.15 0.17 71.4 81.0
DEJ 0.21 0.20 0.17 95.2 90.5
PAC 0.25 0.21 0.18 84.0 72.0
QUE 0.16 0.19 0.18 118.8 112.5
Mean 0.21 0.19 0.18 92.4 89.0
S.D. ±0.04 . ±0.03 ±0.01 +20.1 . ±17.4
S.E. ±0.02 ±0.01 ±0.01 +10.1 ± 8.7
P 16-17 Oct = Base Value 0.38
P 21-22 Oct = Base Value 0.25
P Bed Rest = Ambulatory 0.19
P Recovery = Ambulatory 0.094
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 25. Plasma a-2-globulin concentration (g/100 ml) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 0.54 0.68 0.65 125.9 1201.4
FRE 0.62 0.64 0.61 103.2 98.4
KEE 0.65 0.57 0.56 87.7 86.2
KUL 0.57 0.65 0.66 114.0 115.8
PAR 0.41 0.57 0.44 139.0 107.3
SCH 0.49 0.52 0.53 106.1 108.2
VAN 0..64 0.61 0.57 95.3 89.1
ZIM 0.45 0.56 0.48 124.4 106.7
Mean 0.55 0.60 0.56 112.0 104.0
S.D. ±0.09 ±0.05 ±0.08 ±17.2 +12.0
S.E. ±0.03 ±0.02 ±0.03 + 6.1 _ 4.3
P Bed Rest = Base Value* 0.12
P Recovery = Base Value 0.54
Ambulatory Group
BEN 0.65 0.52 0.50 80.0 76.9
DEJ 0.50 0.48 0.46 96.0 92.0
PAC 0.57 0.59 0.53 103.5 93.0
QUE 0.58 0.61 0.62 105.2 106.9
Mean 0.57 0.55 0.53 96.2 92.2
S.D. ±0.06 ±0.06 +0.07 ±11.5 ±12.3
S.E. ±0.03 ±0.03 ±0.03 ± 5.8 + 6.1
P 16-17 Oct = Base Value 0.55
P 21-22 Oct = Base Value 0.31
P Bed Rest = Ambulatory 0.14
P Recovery = Ambulatory 0.15
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 26. Plasma 8-globulin concentration (g/100 ml) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 0.51 0.64 0.59 125.5 115.7
FRE 0.79 0.81 0.75 102.5 94.9
KEE 0.77 0.89 0.69 115.6 89.6
KUL 0.65 0.75 0.62 115.4 95.4
PAR 0.59 0.72 0.66 122.0 111.9
SCH 0.66 0.89 0.72 134.8 109.1
VAN 0.81 0.80 0.84 98.8 103.7
ZIM 0.60 0.74 0.66 123.3 110.0
Mean 0.67 0.78 0.69 117.2 103.8
S.D. ±0.11 ±0.09 ±0.08 +11.9 ± 9.5
S.E. +0.04 ±0.03 ±0.03 + 4.2 ± 3.3
P Bed Rest = Base Value* 0.007*
P Recovery = Base Value 0.41
Ambulatory Group
BEN 0.71 0.83 0.63 116.9 88.7
DEJ 0.75 0.72 0.72 96.0 96.0
PAC 0.68 0.81 0.70 119.1 102.9
QUE 0.58 0.68 0.62 117.2 106.9
Mean 0.68 0.76 0.67 112.3 98.6
S.D. ±0.07 ±0.07 ±0.05 ±10.9 ± 8.0
S.E. ±0.04 ±0.04 ±0.02 ± 5.5 ± 4.0
P 16-17 Oct = Base Value 0.13
P 21-22 Oct = Base Value 0.67
P Bed Rest = Ambulatory 0.51
P Recovery = Ambulatory 0.38
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 27. Plasma y-globulin concentration (g/100 ml) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 0.81 0.92 0.91 113.6 112.3
FRE 1.18 1.12 0.83 94.9 70.3
KEE 0.99 0.89 0.79 89.9 79.8
KUL 0.65 0.75 0.72 115.4 110.8
PAR 0.74 0.91 0.70 123.0 94.6
SCH 0.87 1.04 0.83 119.5 95.4
VAN 0.78 0.69 0.61 88.5 78.2
ZIM 0.68 0.77 0.62 113.2 91.2
Mean 0.84 0.89 0.75 107.3 91.6
S.D. ±0.18 ±0.15 ±0.11 +13.9 ±15.1
S.E. ±0.06 ±0.05 ±0.04 + 4.9 ± 5.3
P Bed Rest = Base Value * 0.27
P Recovery = Base Value 0.15
Ambulatory Group
BEN 1.24 1.05 0.90 84.7 72.6
DEJ 0.93 1.00 0.84 107.5 90.3
PAC 0.72 0.81 0.60 112.5 83.3
QUE 0.96 1,18 0.98 122.9 102.1
Mean 0.96 1.01 0.83 106.9 87.1
S.D. ±0.21 ±0.15 ±0.16 ±16.1 ±12.4
S.E. ±0.11 ±0.08 ±0.08 ± 8.1 + 6.2
P 16-17 Oct = Base Value 0.62
P.21-22 Oct = Base Value 0.18
P Bed Rest = Ambulatory 0.97
P Recovery = Ambulatory 0.62
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 28. Circulating a-l-globulin (g) for the subjects of the 1973
NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6' 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 3.8 4.5 6.5 118.4 171.1
FRE 5.3 5.2 6.9 98.1 130.2
KEE 6.1 4.4 6.4 72.1 104.9
KUL 4.1 4.9. 4.1 119.5 100.0
PAR 5.2 4.7 5.2 90.4 100.0
SCH 5.5 4.6 5.3 83.6 96.4
VAN 5.5 4.5 5.4 81.8 98.2
ZIM 3.1 5.5 5.2 177.4 167.7
Mean 4.8 4.8 5.6 105.2 121.1
S.D. ±1.0 ±0.4 ±0.9 +33.7 ±31.7
S.E. ±0.4 ±0.1 ±0.3 ±11.9 ±11.2
P Bed Rest = Base Value* 0.94
P Recovery = Base Value 0.090
Ambulatory Group
BEN 4.9 3.8 4.8 77.6 98.0
DEJ 5.8 5.6 5.3 96.6 91.4
PAC 6.6 5.7 5.0 86.4 75.8
QUE 4.2 5.1 4.9 121.4 116.7
Mean 5.4 5.1 5.0 95.5 95.5
S.D. ±1.0 ±0.9 ±0.2 +18.9 ±16.9
S.E. ±0.5 ±0.4 ±0.1 + 9.5 _ 8.5
P 16-17 Oct = Base Value 0.52
P 21-22 Oct = Base Value 0.49
P Bed Rest = Ambulatory 0.61
P Recovery = Ambulatory 0.17
*' Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 29. Circulating a-2-globulin (g) for the subjects of the 1973
NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 14.8 15.2 18.4 102.7 124.3
FRE 16.4 13.9 16.7 84.8 101.8
KEE 18.1 14.0 15.5 77.3 85.6
KUL 14.6 15.1 16.9 103.4 115.8
PAR 11.8 14.1 12.8 119.5 108.5
SCH 11.3 10.4 12.3 92.0 108.8
VAN 14.6 12.6 13.4 86.3 91.8
ZIM 12.6 14.6 14.5 115.9 115.1
Mean 14.3 13.7 15.1 97.7 106.5
S.D. ±2.3 ±1.6 ±2.2 +15.2 ±12.9
S.E. ±0.8 ±0.6 ±0.8 + 5.4 - 4.6
P Bed Rest = Base Value* 0.52
P Recovery = Base Value 0.30
Ambulatory Group
BEN 15.1 13.3 14.1 88.1 93.4
DEJ 13.7 13.4 13.0 97.8 94.9
PAC 15.0 16.0 14.6 106.7 97.3
QUE 15.1 16.4 16.9 108.6 111.9
Mean 14.7 14.8 14.6 100.3 99.4
S.D. ±0.7 ±1.7 ±1.6 + 9.4 ± 8.5
S.E. ±0.3 ±0.8 ±0.8 + 4.7 + 4.3
P 16-17 Oct = Base Value 0.95
P 21-22 Oct = Base Value 0.91
P Bed Rest = Ambulatory 0.77
P Recovery = Ambulatory 0.35
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 30. Circulating 8-globulin (g) for the subjects of the 1973
NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 13.9 14.4 16.7 103.6 120.1
FRE 20.9 17.6 20.6 84.2 98.6
KEE 21.4 21.8 19.1 101.9 89.3
KUL 16.6 17.5 15.9 105.4 95.8
PAR 17.1 17.8 19.1 104.1 111.7
SCH 15.2 17.8 16.6 117.1 109.2
VAN 18.4 16.5 19.8 89.7 107.6
ZIM 16.8 19.2 19.9 114.3 118.5
Mean 17.5 17.8 18.5 102.5 106.4
S.D. ±2.6 ±2.1 ±1.8 ±11.1 ±10.9
S.E. ±0.9 ±0.7 ±0.6 ± 3.9 + 3.9
P Bed Rest = Base Value* 0.70
P Recovery = Base Value 0.20
Ambulatory Group
BEN 16.4 21.3 17.7 129.9 107.9
DEJ 20.5 20.2 20.3 98.5 99.0
PAC 17.9 21.9 19.3 122.3 107.8
QUE 15.1 18.2 16.9 120.5 111.9
Mean 17.5 20.4 18.6 117.8 106.7
S.D. ±2.3 ±1.6 ±1.5 ±13.5 + 5.4
S.E. ±1.2 ±0.8 ±0.8 ± 6.7 + 2.7
P 16-17 Oct = Base Value 0.082
P 21-22 Oct =Base Value 0.092
P Bed Rest = Ambulatory 0.062
P Recovery = Ambulatory 0.96
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 31. Circulating y-globulin (g) for the subjects of the 1973
NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 22.1 20.6 25.8 93.2 116.7
FRE 31.3 24.3 22.7 77.6 72.5
KEE 27.5 21.8 21.9 79.3 79.6
KUL 16.7 17.5 18.4 104.8 110.
PAR 21.4 22.4 20.3 104.7 94.9
SCH 20.0 20.8 19.2 104.0 96.0
VAN 17.8 14.2 14.3 79.8 80.3
ZIM 19.0 20.0 18.7 105.3 105.1
Mean 22.0 20.2 20.2 93.6 94.4
S.D. .±5.0 ±3.1 ±3.4 +12.8 ±15.9
S.E. ±1.8 ±1.1 ±1.2 + 4.5 ± 5.6
P Bed Rest = Base Value* 0.17
P Recovery = Base Value 0.24
Ambulatory Group
BEN 28.8 26.9 25.4 93.4 88.2
DEJ 25.5 28.0 23.7 109.8 92.9
PAC 18.9 22.0 16.6 116.4 87.8
QUE 25.1 31.6 26.6 125.9 106.0
Mean 24.6 27.1 23.1 111.4 93.7
S.D. ±4.1 ±4.0 ±4.5 +13.7 ±8.5
S.E. ±2.1 ±2.0 ±2.2 + 6.8 ±4.3
P 16-17 Oct = Base Value 0.24
P 21-22 Oct = Base Value 0.25
P Bed Rest = Ambulatory 0.050
P Recovery = Ambulatory 0.94
* .,Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 32. Plasma alkaline phosphatase concentration (units/liter) for the
subjects of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 14.5 17.2 17.'3 118.6 119.3
FRE 23.3 24.3 30.0 104.3 128.8
KEE 19.2 21.9 23.6 114.1 122.9
KUL 12.6 14.7 15.8 116.7 125.4
PAR 11.8 14.6 16.4 123.7 139.0
SCH 23.3 27.8 29.7 119.3 127.5
VAN 17.0 18.6 20.4 109.4 120.0
ZIM 14.0 18.0 17.9 128.6 127.9
Mean 17.0 19.6 21.4 116.8 126.4
S.D. ± 4.6 ± 4.7 ± 5.8 ± 7.7 + 6.2
S.E. ± 1.6 ± 1.7 ± 2.0 ± 2.7 + 2.2
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value <0.001*
Ambulatory Group
BEN 19.2 21.4 20.3 111.5 105.7
DEJ 12.9 18.6 19.4 144.2 150.4
PAC 21.6 25.7 26.1 119.0 120.8
QUE 17.3 21.4 20.3 . 123.7 117.3
Mean 17.8 21.8 21.5 124.6 123.6
S.D. ± 3.7 ± 2.9 ± 3.1 ±14.0 ±19.0
S.E. ± 1.8 ± 1.5 ± 1.5 ± 7.0 + 9.5
P 16-17 Oct Base Value 0.011*
P 21-22 Oct = Base Value 0.046*
P Bed Rest = Ambulatory 0.23
P Recovery = Ambulatory 0.70
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 33. Plasma glutamate-oxaloacetate transaminase concentration (units/ml)
for the subjects of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 37.4 29.3 30.4 78.3 81.3
FRE 48.0 30.2 30.2 62.9 62.9
KEE 38.8 29.5 31.2 76.0 80.4
KUL 39.0 33.7 30.4 86.4 77.9
PAR 40.1 29.5 30.6 73.6 76.3
SCH 53.8 35.5 33.3 66.0 61.9
VAN 39.8 30.8 31.5 77.4 79.1
ZIM 42.7 30.1 30.1 70.5 70.5
Mean 42.5 31.1 31.0 73.9 73.8
S.D. ± 5.6 ± 2.3 ± 1.1 + 7.4 ± 7.8
S.E. ± 2.0 ± 0.8 ± 0.4 + 2.6 ± 2.7
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value <0.001*
Ambulatory Group
BEN 38.8 30.2 31.0 77.8 79.9
DEJ 36.9 30.6 31.0 82.9 84.0
PAC 39.0 30.6 30.0 78.5 76.9
QUE 38.0 30.5 29.7 80.3 78.2
Mean 38.2 30.5 30.4 79.9 79.8
S.D. ± 1.0 ± 0.2 ± 0.7 + 2.3 ± 3.1
S.E. ± 0.5 ± 0.1 ± 0.3 + 1.1 ± 1.5
P 16-17 Oct = Base Value <0.001*
P 21-22 Oct = Base Value 0.0014*
P Bed Rest = Ambulatory 0.15
P Recovery = Ambulatory 0.18
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 34. Plasma glutamate-pyruvate transaminase concentration (units/ml)
for the subjects of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 21.3 19.7 19.2 92.5 90.1
FRE 29.7 19.5 20.4 65.7 68.7
KEE 22.2 20.9 20.5 94.1 92.3
KUL 22.5 26.4 22.7 117.3 100.9
PAR 22.0 21.4 20.5 97.3 93.2
SCH 34.0 29.8 25.8 87.6 75.9
VAN 21.6 21.1 21.7 97.7 100.5
ZIM 24.0 20.9 21.4 87.1 89.2
Mean 24.7 22.5 21.5 92.4 88.9
S.D. + 4.7 ± 3.7 ± 2.0 +14.3 ±11.3
S.E. ± 1.6 ± 1.3 ± 0.7 + 5.1 4.0
P Bed Rest = Base Value* 0.16
*P Recovery = Base Value 0.044*
Ambulatory Group
BEN 21.3 19.1 19.4 89.7 91.1
DEJ 23.2 20.5 20.4 88.4 87.9
PAC 22.4 22.1 21.1 98.7 94.2
QUE 21.6 21.3 20.5 98.6 94.9
Mean 22.1 20.8 20.4 93.9 92.0
S.D. ± 0.9 ± 1.3 ± 0.7 + 5.6 ± 3.2
S.E. ± 0.4 0.6 ± 0.4 + 2.8 ± 1.6
P 16-17 Oct = Base Value 0.12
P 21-22 Oct = Base Value 0.019*
P Bed Rest = Ambulatory 0.85
P Recovery = Ambulatory 0.60
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 35. Plasma total lactate dehydrogenase concentration (units/ml) for
the subjects of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 301 251 264 83.4 87.7
FRE 274 245 260 89.4 94.9
KEE 287 253 272 88.2 94.8
KUL 291 248 263 85.2 90.4
PAR 285 252 280 88.4 98.2
SCH 281 242 277 86.1 98.6
VAN 287 261 278 90.9 96.9
ZIM 279 268 284 96.1 101.8
Mean 286 252 272 88.5 95.4
S.D. ± 8 ± 8 - 9 + 3.9 ± 4.6
S.E. + 3 ± 3 3 + 1.4 ± 1.6
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value 0.027*
Ambulatory Group
BEN 277 244 256 88.1 92.4
DEJ 285 264 249 92.6 87.4
PAC 290 278 272 95.9 93.8
QUE 279 249 263 89.2 94.3
Mean 283 259 260 91.5 92.0
S.D. ± 6 ±15 ±10 + 35 + 3.2
S.E. + 3 8 5 + 1.8 ± 1.6
p 16-17 Oct = Base Value 0.015*
p 21-22 Oct = Base Value 0.015*
P Bed Rest = Ambulatory 0.23
P Recovery = Ambulatory 0.21
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 36. Plasma LDH-1 isoenzyme concentration (units/ml) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 127.0 76.9 112.4 60.6 88.5
FRE 122.0 68.8 107.1 56.4 87.8
KEE 106.5 75.5 108.2 70.9 101.6
KUL .100.8 70.4 98.0 69.8 97.2
PAR 113.0 57.6 98.9 51.0 87.5
SCH 108.1 49.9 102.1 46.2 94.4
VAN 112.5 65.3 109.5 58.0 97.3
ZIM 116.7 72.3 114.1 62.0 97.8
Mean 113.3 67.1 106.3 59.4 94.0
S.D. ± 8.5 ± 9.2 ± 6.0 + 8.5 ± 5.4
S.E. ± 3.0 ± 3.3 ± 2.1 + 3.0 ± 1.9
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value 0.019*
Ambulatory Group
BEN .122.3 66.4 118.8 54.3 97.1
DEJ 119.0 66.5 102.2 55.9 85.9
PAC 127.0 69.4 101.7 54.6 80.1
QUE 106.4 64.4 103.8 60.5 97.6
Mean 118.7 66.7 106.6 56.3 90.2
S.D. ± 8.8 ± 2.1 ± 8.2 + 2.9 ± 8.6
S.E. ± 4.4 ± 1.0 ± 4.1 + 1.4 ± 4.3
P 16-17 Oct = Base Value <0.001*
P 21-22 Oct = Base Value 0.12
P Bed Rest = Ambulatory 0.51
P Recovery = Ambulatory 0.36
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 37. Plasma LDH-2 isoenzyme concentration (units/ml) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 122.6 88.7 86.6 72.3 70.6
FRE 98.2 76.9 80.6 78.3 82.1
KEE 97.0 98.2 93.7 101.2 96.6
KUL 145.9 88.5 76.9 60.7 52.7
PAR 96.0 94.2 92.2 98.1 96.0
SCH 80.3 92.3 85.3 114.9 106.2
VAN 87.8 91.7 80.7 104.4 91.9
ZIM 81.1 99.8 89.0 123.1 109.7
Mean 101.1 91.3 85.6 94.1 88.2
S.D. ±22.5 ± 7.1 ± 5.9 +21.7 ±19.0
S.E. ± 7.9 ± 2.5 ± 2.1 + 7.7 ± 6.7
P Bed Rest = Base Value* 0.32
P Recovery = Base Value 0.13
Ambulatory Group
BEN 80.1 73.1 71.6 91.3 89.4
DEJ 97.0 82.4 72.6 84.9 74.8
PAC 96.0 114.5 73.0 119.3 76.0
QUE 96.3 102.8 87.4 106.7 90.8
Mean 92.4 93.2 76.2 100.6 82.8
S.D. ± 8.2 ±18.9 ± 7.5 ±15.5 + 8.5
S.E. ± 4.1 ± 9.4 ± 3.8 7.7 4.3
P 16-17 Oct = Base Value 0.91
P 21-22 Oct = Base Value 0.034*
P Bed Rest = Ambulatory 0.61
P Recovery = Ambulatory 0.60
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 38. Plasma LDH-3 isoenzyme concentration (units/ml) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value . Bed Rest Recovery 23-24 Sep 23-24.Sep
CAP 39.3 51.6 41.3 131.3 105.1
FRE 38.0 60.5 44.9 159.2 118.2
KEE 46.9 59.7 43.4 127.3 92.5
KUL 32.8 62.6 53.5 190.9 163.1
PAR 52.8 64.5 59.5 122.2 112.7
SCH 36.0 68.3 57.4 189.7 159.4
VAN 47.5 53.4 50.4 112.4 . 106.1
ZIM 47.5 60.7 51.0 127.8 107.4
Mean 42.6 60.2 50.2 145.1 120.6
S.D. ± 7.0 ± 5.5 ± 6.6 +30.9 ±26.2
S.E. ± 2.5 ± 1.9 + 2.3 ±10.9 ± 9.3
P Bed Rest = Base Value* 0.001*
P Recovery = Base Value 0.047*
Ambulatory Group
BEN 44.4 60.4 41.1 136.0 92.6
DEJ 45.5 71.8 41.5 157.8 91.2
PAC 40.7 70.8 56.5 174.0 138.8
QUE 45.0 61.0 46.8 135.6 104.0
Mean 43.9 66.0 46.5 150.9 106.7
S.D. ± 2.2 ± 6.1 ± 7.2 ±18.6 ±22.2
S.E. ± 1.1 ± 3.1 ± 3.6 ± 9.3 ±11.1
P 16-17 Oct = Base Value 0.009*
P 21-22 Oct = Base Value 0.61
P Bed Rest = Ambulatory 0.74
P Recovery = Ambulatory 0.39
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 39. Plasma LDH-4 isoenzyme concentration (units/ml) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24.Sep 23-24 Sep
CAP 3.0 .15.6 12.4 520.0 413.3
FRE 3.2 19.4 14.9 606.3 465.6
KEE 15.9 9.1 14.5 57.2 91.2
KUL . 6.6 10.4 18.1 157.6 274.2
PAR 16.9 14.9 17.6 88.2 104.1
SCH 12.4 12.0 18.2 96.8 146.8
VAN 18.6 31.7 20.9 170.4 112.4
ZIM 20.8 15.0 17.8 72.1 85.6
Mean 12.2 16.0 16.8 221.1 211.7
S.D. ± 7.0 ± 7.1 ± 2.7 ±216.0 ±153.6
S.E. ± 2.5 ± 2.5 ± 0.9 + 76.4 ± 54.3
P Bed Rest = Base Value* 0.27
P Recovery = Base Value 0.059
Ambulatory Group
BEN 15.1 21.8 13.1 144.4 86.8
DEJ 11.8 23.6 17.6 200.0 149.2
PAC 14.6 9.3 23.6 - 63.7 161.6
QUE 12.5 13.2 13.3 105.6 106.4
Mean 13.5 17.0 16.9 128.4 126.0
S.D. ± 1.6 ± 6.8 ± 4.9 +58.0 ±35.2
S.E. ± 0.8 ± 3.4 ± 2.5 +29.0 ±17.6
P 16-17 Oct = Base Value 0.42
P 21-22 Oct = Base Value 0.26
P Bed Rest = Ambulatory 0.43
P Recovery 0.31
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 40. Plasma LDH-5 isoenzyme concentration (units/ml) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 9.1 18.2 11.3 200.0 124.2
FRE 12.6 19.4 12.5 154.0 99.2
KEE 20.7 10.5 12.2 50.7 58.9
KUL 4.9 16.1 16.5 328.6 336.7
PAR 6.3 20.8 11.8 330.2 187.3
SCH 44.2 19.5 14.0 44.1 31.7
VAN 20.6 18.9 16.5 91.7 80.1
ZIM 12.9 20.2 12.1 156.6 93.8
Mean 16.4 18.0 13.4 169.5 126.5
S.D. ±12.7 ± 3.3 ± 2.1 +112.4 ± 96.7
S.E. ± 4.5 ± 1.2 ± 0.7 + 39.7 ± 34.2
P Bed Rest = Base Value* 0.75
P Recovery = Base Value 0.51
Ambulatory Group
BEN 15.1 22.3 11.4 147.7 75.5
DEJ 11.7 19.7 15.1 168.4 129.1
PAC 11.7 14.0 17.2 119.7 147.0
QUE 18.8 7.6 11.7 40.4 62.2
Mean 14.3 15.9 13.9 119.1 103.5
S.D. ± 3.4 ± 6.5 ± 2.8 ± 56.1 ± 41.0
S.E. ±.1.7 ± 3.3 ± 1.4 + 28.1 ± 20.5
P 16-17 Oct = Base Value 0.75
P 21-22 Oct = Base Value 0.88
P Bed Rest = Ambulatory 0.42
P Recovery = Ambulatory 0.66
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 41. Urine volume (liters/24 hr) for the subjects of the 1973
NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 1.35 0.36 0.44 26.7 32.6
FRE 1.00 0.41 -- 41.0 --
KEE 1.74 0.93 1.16 53.4 66.7
KUL 1.74 1.04 1.72 59.8 98.9
PAR 2.55 1.98 2.90 77.6 113.7
SCH 2.33 2.20 2.77 94.4 118.9
VAN 0.90 0.43 0.67 47.8 74.4
ZIM 1.20 0.32 1.24 26.7 103.3
Mean 1.60 0.96 1.56 53.4 86.9
S.D. ±0.60 ±0.75 ±0.97 ±23.7 ±30.7
S.E. ±0.21 ±0.27 ±0.36 + 8.4 ±11.6
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value 0.51
Ambulatory Group
BEN 1.22 1.48 1.32 121.3 108.2
DEJ 1.30 0.92 0.99 70.8 76.2
PAC 1.02 0.80 1.35 78.4 132.4
QUE 1.93 0.60 1.62 31.1 83.9
Mean 1.37 0.95 1.32 75.4 100.2
S.D. ±0.39 ±0.38 ±0.26 ±37.0 ±25.4
S.E. ±0.20 ±0.19 ±0.13 +18.5 ±12.7
P 16-17 Oct = Base Value 0.30
P 21-22 Oct = Base Value 0.78
P Bed Rest = Ambulatory 0.23
P Recovery = Ambulatory 0.49
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 42. Urine specific gravity (24 hr) for the subjects of the 1973
NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 1.013 1.022 1.015 169.2 115.4
FRE 1.013 1.018 -- 138.5 --
KEE 1.012 1.020 1.012 166.7 100.01
KUL 1.015 1.016 1.008 106.7 53.3
PAR 1.009 1.007 1.008 77.8 88.9
SCH 1.008 1.007 1.004 87.5 50.0
VAN 1.015 1.017 1.016 113.3 106.7
ZIM 1.018 1.020 1.018 111.1 100.0
Mean 1.013 1.016 1.012 121.4 87.8i
S.D. ±0.003 ±0.006 ±0.005 +33.9 ±25.9
S.E. ±0.001 ±0.002 ±0.002 +12.0 ± 9.8
P Bed Rest = Base Value* 0.72
P Recovery = Base Value 0.32
Ambulatory Group
BEN 1.015 1.014 1.016 93.3 106.7
DEJ 1.017 1.019 1.009 111.8 52.9
PAC 1.017 1.016 1.014 94.1 . 82.4
QUE 1.011 1.015 1.017 136.4 154.5
Mean 1.015 1.016 1.014 108.9 99.1
S.D. ±0.003 ±0.002 ±0.004 +20.2 ±43.0
S.E. ±0.001 ±0.001 ±0.002 +10.1 ±21.5
P 16-17 Oct = Base Value 0.47
P 21-22 Oct = Base Value 0.76
P Bed Rest = Ambulatory 0.52
P Recovery = Ambulatory 0.59
*-Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 43. Urine osmotic activity (osmols/24 hr) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 0.744 0.295 0.242 39.7 32.5
FRE 0.571 0.233 -- 40.8 --
KEE 0.826 0.708 0.538 85.7 65.1
KUL 0.814 0.569 0.600 69.9 73.7
PAR 0.955 0.466 0.924 48.8 96.8
SCH 0.799 0.492 0.542 61.6 67.8
VAN 0.353 0.312 0.475 88.4 134.6
ZIM 0.996 0.288 0.847 28.9 85.0
Mean 0.757 0.420 0.595 58.0 79.4
S.D. ±0.208 ±0.166 ±0.230 ±22.1 ±31.5
S.E. ±0.074 ±0.059 ±0.087 + 7.8 ±11.9
P Bed Rest = Base Value* 0.003*
P Recovery = Base Value 0.046*
Ambulatory Group
BEN 0.792 0.751 0.811 94.8 102.4
DEJ 1.051 0.761 0.439 72.4 41.8
PAC 0.950 0.523 0.785 55.1 82.6
QUE 0.840 0.343 0.929 40.8 110.6
Mean 0.908 0.595 0.741 65.8 84.4
S.D. ±0.116 ±0.200 ±0.211 +23.3 ±30.7
S.E. ±0.058 ±0.100 ±0.105 ±11.6 ±15.4
P 16-17 Oct = Base Value 0.052
P 21-22 Oct = Base Value 0.37
P Bed Rest = Ambulatory 0.58
P Recovery = Ambulatory 0.80
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 44. Urine pH (24 hr) for the subjects of the 1973 NASA/Ames Female
Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 6.51 5.93 5.92 91.1 90.9
FRE 7.01 5.69 -- 81.2 --
KEE 6.78 6.16 7.30 90.9 107.7
KUL 7.16 6.26 5.71 87.4 79.7
PAR 6.66 6.34 6.28 95.2 94.3
SCH 7.11 5.78 6.35 81.3 89.3
VAN 6.41 6.32 6.75 98.6 105.3
ZIM 6.89 5.71 6.82 82.9 99.0
Meah 6.82 6.02 6.45 88.6 95.2
S.D. ±0.28 ±0.28 ±0.55 + 6.5 ± 9.7
S.E. ±0.10 ±0.10 ±0.21 + 2.3 ± 3.7
P Bed Rest = Base Value* 0.002*
P Recovery = Base Value 0.23
Ambulatory Group
BEN 6.42 6.37 7.46 99.2 116.2
DEJ 7.17 5.21 6.08 72.7 84.8
PAC 5.56 6.66 5.90 119.8 106.1
QUE 6.78 6.32 6.64 93.2 97.9
Mean 6.48 6.14 6.52 96.2 101.3
S.D. ±0.69 ±0.64 ±0.70 +19.4 ±13.3
S.E. ±0.34 ±0.32 ±0.35 ± 9.7 + 6.6
P 16-17 Oct = Base Value 0.63
P 21-22 Oct = Base Value 0.94
P Bed Rest = Ambulatory 0.32
P Recovery = Ambulatory 0.40
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 45. Urine chloride excretion rate (mmol/24 hr) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 163 42 48 25.8 29.4
FRE 152 37 -- 24.3 --
KEE 211 108 91 51.2 43.1
KUL 241 96 141 39.8 58.5
PAR 241 85 154 35.3 63.9
SCH 235 93 144 39.6 61.3
VAN 124 56 120 45.2 96.8
ZIM 225 43 202 19.1 89.8
Mean 199 70 129 35.0 63.3
S.D. ± 46 ± 28 ± 49 11.1 ± 23.8
S.E. ± 16 ± 10 ± 19 + 3.9 ± 9.0
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value 0.0041*
Ambulatory Group
BEN 182 156 178 85.7 97.8
DEJ 241 125 126 51.9 52.3
PAC 144 107 167 74.3 116.0
QUE 239 63 251 26.4 105.0
Mean 201 113 180 59.6 92.8
S.D. ± 47 ± 39 ± 52 26.2 ± 28.0
S.E. ± 24 ± 19 ± 26 + 13.1 14.0
P 16-17 Oct Base Value 0.087
P 21-22 Oct = Base Value 0.56
P Bed Rest = Ambulatory 0.041*
P Recovery = Ambulatory 0.096
* Value of P <0.05 indicates a statistically significant difference between the
two populations compared.
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Table 46. Urine sodium excretion rate (mmol/24 hr) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 - 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 159 39 46 24.5 28.9
FRE 159 49 -- 30.8 --
KEE 206 130 Ill 63.1 53.9
KUL 256 147 146 57.4 57.0
PAR 259 126 183 48.6 70.7
SCH 288 120 162 41.7 56.3
VAN 121 66 138 54.5 114.0
ZIM 217 51 236 23.5 108.8
Mean 208 91 146 43.0 69.9
S.D. _ 58 + 44 ± 59 ±15.3 ±30.9
S.E. + 21 ± 15 ± 22 + 5.4 ±11.7
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value 0.025*
Ambulatory Group
BEN 170 179 185 105.3 108.8
DEJ 267 121 126 45.3 47.2
PAC 127 145 189 114.2 148.8
QUE 267 81 275 30.3 103.0
Mean 208 132 194 73.8 102.0
S.D. 71 ± 41 ± 61 ± 42.1 41.8
S.E. ± 35 ± 21 ± 31 ± 21.1 + 20.9
P 16-17 Oct = Base Value 0.24
P 21-22 Oct = Base Value 0.77
P Bed Rest = Ambulatory 0.086
P Recovery = Ambulatory 0.18
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 47. Urine potassium excretion rate (mmol/24 hr) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 46.1 24.7 18.5 53.6 40.1
FRE 32.9 12.7 -- 38.6 --
KEE .67.2 52.8 61.2 78.6 91.1
KUL . 85.9 42.0 32.4 48.9 37.7
PAR 79.2 46.3 67.7 58.5 85.5
SCH 65.3 39.6 34.6 60.6 53.0
VAN 41.8 19.4 20.2 46.4 48.3
ZIM 77.5 15.6 54.0 20.1 69.7
Mean 62.0 31.6 41.2 50.7 60.8
S.D. ±19.5 ±15.3 ±19.8 ±17.1 ±21.6
S.E. 6.9 5.4 7.5 + 6.1 8.1
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value 0.0051*
Ambulatory Group
BEN 53.3 50.4 90.5 94.6 169.8
DEJ 59.0 58.1 25.4 98.5 . 43.1
PAC 48.0 30.7 45.4 64.0 94.6
QUE 60.0 29.8 44.2 49.7 73.7
Mean 55.1 42.3 51.4 76.7 95.3
S.D. ± 5.6 ±14.2 ±27.6 +23.7 ±54.0
S.E. ± 2.8 ± 7.1 ±13.8 +11.9 ±27.0
P 16-17 Oct = Base Value 0.16
P 21-22 Oct = Base Value 0.82
P Bed Rest = Ambulatory 0.052
P Recovery = Ambulatory 0.16
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 48. Urine Na/K ratio (24 hr) for the subjects of the 1973
NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 3.45 1.58 2.49 45.8 72.2
FRE 4.83 3.86 -- 79.9 --
KEE 3.07 2.46 1.81 80.1 59.0
KUL 2.98 3.50 4.51 117.4 151.3
PAR 3.27 2.72 2.70 83.2 82.6
SCH 4.41 3.03 4.68 68.7 106.1
VAN 2.89 3.40 6.83 117.6 236.3
ZIM 2.80 3.27 4.37 116.8 156.1
Mean 3.46 2.94 3.91 88.7 123.4
S.D. ±0.75 ±0.76 ±1.71 +26.4 ±62.4
S.E. ±0.27 ±0.29 ±0.65 + 9.3 ±23.6
P Bed Rest Base Value* 0.18
P Recovery = Base Value 0.39
Ambulatory Group
BEN 3.19 3.55 2.04 111.3 63.9
DEJ 4.53 2.08 4.96 45.9 109.5
PAC 2.65 4.72 4.16 178.1 157.0
QUE 4.45 2.72 6.22 61.1 139.8
Mean 3.71 3.27 4.35 99.1 117.6
S.D. ±0.93 ±1.14 ±1.76 +59.6 ±40.8
S.E. ±0.47 ±0.57 ±0.88 +29. ±20.4
P 16-17 Oct = Base Value 0.70
P 21-22 Oct = Base Value 0.41
P. Bed Rest = Ambulatory 0.68
P Recovery = Ambulatory 0.87
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 49. Urine magnesium excretion (mmol/2 4 hr) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 2.58 2.08 0.85 80.6 32.9
FRE 2.66 2.38 -- 89.5 --
KEE 2.78 5.62 1.90 202.2 68.3
KUL 4.20 7.03 2.41 167.4 .57.4
PAR 4.04 4.39 5.25 108.7 130.0
SCH 2.83 5.48 2.19 193.6 77.4
VAN 2.27 1.72 2.09 75.8 92.1
ZIM 4.35 1.93 3.94 44.4 90.6
Mean 3.21 3.83 2.66 120.3 78.4
S.D. ±0.84 ±2.06 ±1.46 ±59.4 ±30.6
S.E. ±0.30 ±0.73 ±0.55 +21.0 ±11.6
P Bed Rest = Base Value* 0.40
P Recovery = Base Value 0.15
Ambulatory Group
BEN 3.74 5.87 2.87 157.0 76.7
DEJ 2.82 4.17 1.64 147.9 58.2
PAC 2.34 3.59 3.60 153.4 153.8
QUE 5.60 3.08 4.66 55.0 83.2
Mean 3.63 4.18 3.19 128.3 93.0
S.D. ±1.44 ±1.21 ±1.27 +49.0 ±41.9
S.E. ±0.72 ±0.61 ±0.63 ±24.5 ±21.0
P 16-17 Oct = Base Value 0.63
P 21-22 Oct = Base Value 0.50
P Bed Rest = Ambulatory 0.82
P Recovery = Ambulatory 0.52
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 50. Urine calcium excretion (mmol/24 hr) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 3.84 2.70 1.59 70.3 41.4
FRE 2.76 3.30 -- 119.6 --
KEE 5.20 6.15 2.08 118.3 40.0
KUL 5.77 5.94 4.15 102.9 71.9
PAR 5.31 5.36 6.66 100.9 125.4
SCH 4.51 5.40 3.64 119.7 80.7
VAN 2.35 1.37 2.44 58.3 103.8
ZIM 5.59 2.08 5.32 37.2 95.2
Mean 4.42 4.04 3.70 90.9 79.8
S.D. ±1.31 ±1.89 ±1.84 +31.7 +31.7
S.E. ±0.46 ±0.67 ±0.69 ±11.2 ±12.0
P Bed Rest = Base Value* 0.49
P Recovery = Base Value 0.15
Ambulatory Group
BEN 4.16 5.32 3.79 127.9 91.1
DEJ 4.65 4.99 2.56 107.3 55.1
PAC 4.66 3.87 4.70 83.0 100.9
QUE 3.64 2.24 4.59 61.5 126.1
Mean 4.28 4.11 3.91 94.9 93.3
S.D. ±0.48 ±1.39 ±0.99 +28.9 ±29.4
S.E. ±0.24 ±0.69 ±0.49 +14.4 ±14.7
P 16-17 Oct = Base Value 0.78
P 21-22 Oct = Base Value 0.60
P Bed Rest = Ambulatory 0.84
P Recovery Ambulatory 0.50
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 51. Urine phosphate excretion (mmol/24 hr) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 17.0 13.6 8.8 80.0 51.8
FRE 16.8 15.1 -- 89.9 --
KEE 28.7 30.9 23.1 107.7 80.5
KUL 34.4 28.6 20.3 83.1 59.0
PAR 23.2 25.8 36.2 111.2 156.0
SCH 18.8 24.9 18.6 132.4 98.9
VAN 17.8 11.4 13.7 64.0 77.0
ZIM 24.5 11.7 34.4 47.8 140.4
Mean 22.7 20.3 22.2 89.5 94.8
S.D. ±6.4 ±8.1 ±10.1 +27.2 ±39.8
S.E. ±2.2 ±2.9 ± 3.8 ± 9.6 ±15.0
P Bed Rest = Base Value* 0.30
P Recovery = Base Value 0.73
Ambulatory Group
BEN 23.3 32.2 24.0 138.2 103.0
DEJ 26.8 29.5 11.5 110.1 42.9
PAC 19.0 21.0 29.0 110.5 152.6
QUE 21.8 10.7 32.2 49.1 147.7
Mean 22.7 23.4 24.2 102.0 111.6
S.D. ±3.2 ±9.7 ±9.1 +37.6 ±50.9
S.E. ±1.6 ±4.8 ±4.5 ±18.8 ±25.5
P 16-17 Oct = Base Value 0.89
P 21-22 Oct = Base Value 0.83
P Bed Rest = Ambulatory 0.52
P Recovery = Ambulatory 0.56
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 52. Urine total nitrogen excretion rate (g/24 hr) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 8.84 4.67 3.03 52.8 34.3
FRE 6.32 3.36 -- 53.2 --
KEE 12.61 12.61 7.36 100.0 58.4
KUL 16.88 10.22 6.09 60.5 . 36.1
PAR 12.74 7.77 11.94 61.0 93.7
SCH 6.96 9.04 - 4.34 129.9 62.4
VAN 7.60 3.50 5.28 46.1 69.5
ZIM 12.95 3.26 11.00 25.2 84.9
Mean 10.61 6.80 7.01 66.1 62.8
S.D. ±3.72 ±3.61 ±3.35 +33.2 ±22.5
S.E. ±1.32 ±1.28 ±1.26 +11.7 ± 8.5
P Bed Rest = Base Value* 0.022*
P Recovery = Base Value 0.017*
Ambulatory Group
BEN 10.36 9.89 8.94 95.5 86.3
DEJ 13.45 13.35 3.90 99.3 29.0
PAC 10.63 4.88 9.38 45.9 88.2
QUE 7.06 7.87 13.28 111.5. 188.1
Mean 10.38 9.00 8.88 88.1 97.9
S.D. +2.61 ±3.56 ±3.85 +28.9 ±66.1
S.E. ±1.31 ±1.78 ±1.92 ±14.5 ±33.1
P 16-17 Oct = Base Value 0.42
P 21-22 Oct = Base Value 0.67
P Bed Rest = Ambulatory 0.29
P Recovery = Ambulatory 0.22
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
69
Table 53. Urine ammonia excretion rate (mmol/24 hr) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 25.0 14.9 11.8 59.6 47.2
FRE 18.2 24.7 -- 135.7 --
KEE 30.7 36.2 22.1 117.9 72.0
KUL 29.5 26.2 25.7 . 88.8 87.1
PAR 34.3 26.6 50.6 77.6 147.5
SCH 23.0 36.7 26.6 159.6 115.7
VAN 21.8. 12.2 13.4 56.0 61.5
ZIM .24.0 12.7 17.3 52.9 72.1
Mean 25.8 23.8 23.9 93.5 86.2
S.D. ±5.3 ±9.8 ±13.1 +40.0 ±34.5
S.E. ±1.9 ±3.5 + 4.9 +14.2 ±13.1
P Bed Rest = Base Value* 0.56
P Recovery = Base Value 0.46
Ambulatory Group
BEN 30.5 40.1 11.3 131.5 37.0
DEJ 22.3 32.6 11.5 146.2 51.6
PAC 39.8 15.8 36.0 39.7 90.5
QUE 23.5 19.4 25.0 82.6 106.4
Mean 29.0 27.0 21.0 100.0 71.4
S.D. ±8.0 ±11.3 ±11.9 +48.5 ±32.5
S.E. ±4.0 ± 5.7 ± 6.0 +24.3 ±16.2
P 16-17 Oct Base Value 0.82
P 21-22 Oct = Base Value 0.17
P Bed Rest = Ambulatory 0.81
P Recovery = Ambulatory 0.50
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 54. Urine urea excretion rate (mmol/24 hr) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group.
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 456 154 99 33.8 21.7
FRE 273 i1 -- 40.7 --
KEE 535 399 257 74.6 48.0
KUL 624 300 269 48.1 43.1
PAR 677 372 473 54.9 69.9
SCH 331 292 299 88.2 90.3
VAN 260 131 177 50.4 68.1
ZIM 426 123 334 28.9 78.4
Mean 448 235 273 52.5 59.9
S.D. ±156 ±119 ±118 +20.1 ±23.5
S.E. ± 55 ± 42 + 45 + 7.1 ± 8.9
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value 0.008*
Ambulatory Group
BEN 393 332 .315 84.5 80.2
DEJ 549 421 166 76.7 30.2
PAC 359 194 323 54.0 90.0
QUE 312 .136 368 43.6 117.9
Mean 403 271 293 64.7 79.6
S.D. ±103 ±130 ±88 ±19.1 ±36.6
S.E. ± 51 ± 65 ±44 + 9.6 ±18.3
P 16-17 Oct = Base Value 0.015*
P 21-22 Oct = Base Value 0.33
P Bed Rest = Ambulatory 0.34
P Recovery = Ambulatory 0.30
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 55. Urine creatinine excretion rate (mmol/24 hr) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 10.32 7.56 6.02 73.3 58.3
FRE 8.66 5.40 -- 62.4 --
KEE 9.31 8.30 5.76 89.2 61.9
KUL 10.49 7.44 6.72 70.9 64.1
PAR 10.22 7.42 11.16 72.6 109.2
SCH 8.23 8.62 7.73 104.7 93.9
VAN 8.50 5.02 5.66 59.1 66.6
ZIM 10.27 4.22 9.55 41.1 93.0
Mean 9.50 6.75 7.51 71.7 78.1
S.D. ±0.93 ±1.63 ±2.12 +19.2 ±20.1
S.E. ±0.33 ±0.58 ±0.80 + 6.8 ± 7.6
P Bed Rest = Base Value* 0.004*
P Recovery = Base Value 0.032*
Ambulatory Group
BEN 9.10 8.59 9.10 94.4 100.0
DEJ 10.08 9.10 4.80 90.3 47.6
PAC 9.26 6.82 10.82 73.7 116.8
QUE 8.06 4.97 8.88 61.7 110.2
Mean 9.13 7.37 8.40 80.0 93.7
S.D. ±0.83 ±1.87 ±2.55 +15.1 ±31.5
S.E. ±0.41 ±0.94 ±1.28 + 7.6 ±15.7
P 16-17 Oct = Base Value 0.063
P 21-22 Oct = Base Value 0.67
P Bed Rest = Ambulatory 0.47
P Recovery = Ambulatory 0. 34
* Value of P <0,05 indicates a statistically significant difference between
the two populations compared.
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Table 56. Urine creatine excretion rate (mmol/24 hr) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 0.85 1.24 0.51 145.9 60.0
FRE 1.34 0.95 -- 70.9 --
KEE 2.50 2.90 3.28 116.0 131.2
KUL 3.66 3.62 1.46 98.9 39.9
PAR 3.63 1.60 1.21 44.1 33.3
SCH 2.56 2.87 1.57 112.1 61.3
VAN 1.80 2.52 1.16 140.0 64.4
ZIM 1.30 1.30 1.48 . 100.0 113.8
Mean 2.21 2.13 1.52 103.5 72.0
S.D. ±1.06 ±0.98 ±0.85 +33.8 ±36.7
S.E. ±0.38 ±0.35 ±0.32 ±11.9 ±13.9
P Bed Rest = Base Value* 0.80
P Recovery = Base Value 0.12
Ambulatory Group
BEN 1.54 1.78 0.66 115.6 42.9
DEJ 4.03 1.82 2.95 45.2 73.2
PAC 2.37 2.68 1.41 113.1 59.5
QUE 2.06 0.96 1.00 46.6 48.5
Mean 2.50 1.81 1.51 80.1 56.0
S.D. ±1.08 ±0.70 ±1.01 +39.5 ±1.3.4
S.E. ±0.54 ±0.35 ±0.51 . ±19.8 ± 6.7
P 16-17 Oct = Base Value 0.33
P 21-22 Oct = Base Value <0.001*
P Bed Rest = Ambulatory Q.31
P Recovery = Ambulatory 0.43
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 57. Urine hydroxyproline excretion rate (mmol/24 hr) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 0.332 0.253 0.117 76.2 35.2
FRE ........ --
KEE 0.433 0.330 0.186 76.2 43.0
KUL 0.425 0.416 0.198 97.9 46.6
PAR 0.455 0.227 0.380 49.9 83.5
SCH 0.469 0.325 0.303 69.3 64.6
VAN 0.356 0.157 0.191 44.1 53.7
ZIM 0.396 0.124 0.292 31.3 73.7
Mean 0.409 0.262 0.238 63.6 57.2
S.D. ±0.051 ±0.103 ±0.090 +22.9 ±17.5
S.E. ±0.019 ±0.039 ±0.034 + 8.6 ± 6.6
P Bed Rest = Base Value* 0.005*
P Recovery = Base Value <0.001*
Ambulatory Group
BEN 0.241 0.436 0.193 180.9 80.1
DEJ 0.415 0.280 0.029 67.5 7.0
PAC 0.338 0.153 0.208 45.3 61.5
QUE 0.074 0.136 0.286 183.8 386.5
Mean 0.267 0.251 0.179 119.4 133.8
S.D. ±0.147 ±0.139 ±0.108 ±73.3 ±171.3
S.E. ±0.074 ±0.069 ±0.054 ±36.6 ± 85.7
P 16-17 Oct = Base Value 0.87
P 21-22 Oct = Base Value 0.53
P Bed Rest = Ambulatory 0.086
P Recovery = Abulatory 0.25
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 58. Urine glucose excretion rate (mmol/24 hr) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 0.401 0.084 0.139 20.9 34.7
FRE 0.526 0.149 -- 28.3 --
KEE 0.518 0.451 -- 87.1 --
KUL 0.691 0.329 0.502 47.6 72.6
PAR 0.588 0.449 1.162 76.4 197.6
SCH 0.922 0.473 0.936 51.3 101.5
VAN 0.302 0.197 0.233 65.2 77.2
ZIM 0.386 0.108 0.437 28.0 113.2
Mean 0.542 0.280 0.568 50.6 99.5
S.D. ±0.197 ±0.165 ±0.402 +24.2 ±55.2
S.E. ±0.070 ±0.058 ±0.164 + 8.6 ±22.5
P Bed Rest = Base Value* 0.001*
P Recovery = Base Value 0.88
Ambulatory Group
BEN 0.480 0.386 0.386 80.4 80.4
DEJ 0.494 0.317 0.288 64.2 58.3
PAC 0.406 0.211 0.355 52.0 87.4
QUE 0.526 0.185 0.509 35.2 96.8
Mean 0.477 0.275 0.385 58.0 80.7
S.D. ±0.051 ±0.094 ±0.093 +19.1 ±16.4
S.E. ±0.025 ±0.047 ±0.046 + 9.6 ± 8.2
P 16-17 Oct = Base Value 0.029*
P 21-22 Oct = Base Value 0.11
P Bed Rest = Ambulatory 0.61
P Recovery = Ambulatory 0.53
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 59. Urine citrate excretion rate (mmol/24 hr) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 1.07 0.98 0.77 91.6 72.0
FRE 2.43 1.42 -- 58.4 --
KEE 2.10 3.48 3.46 165.7 164.8
KUL 2.18 2.54 3.26 116.5 149.5
PAR 4.25 5.46 7.70 128.5 181.2
SCH 3.50 5.75 2.90 164.3 82.9
VAN 1.92 2.15 2.95 112.0 153.6
ZIM 2.86 1.75 3.84 61.2 134.3
Mean 2.54 2.94 3.55 112.3 134.0
S.D. ±0.99 ±1.81 ±2.08 +41.0 ±41.3
S.E. ±0.35 ±0.64 ±0.79 +14.5 ±15.6
P Bed Rest = Base Value* 0.36
P Recovery = Base Value 0.091
Ambulatory Group
BEN 2.61 3.53 6.39 135.2 244.8
DEJ 3.12 3.32 2.71 106.4 86.9
PAC 2.39 4.10 3.67 171.5 153.6
QUE 4.63 3.66 4.60 79.0 99.4
Mean 3.19 3.65 4.34 123.0 146.2
S.D. ±1.01 ±0.33 ±1.57 +39.6 ±71.8
S.E. ±0.50 ±0.16 ±0.78 +19.8 ±35.9
P 16-17 Oct = Base Value 0.47
P 21-22 Oct = Base Value 0.31
P Bed Rest = Ambulatory 0.67
P Recovery = Ambulatory 0.73
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.(
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Table 60. Urine 17-OH corticosteroid excretion rate (pmol/24 hr) for the
subjects of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 1.93 0.94 1.24 48.7 64.2
FRE 1.53 4.63 -- 302.6 --
KEE 3.51 2.27 5.13 64.7 146.2
KUL 3.51 1.27 0.97 36.2 27.6
PAR . 4.55 2.32 1.69 51.0 37.1
SCH -- -- -- --
VAN 3.65 0.94 0.24 25.8 6.6
ZIM 2.15 0.20 1.45 9.3 67.4
Mean 2.98 1.80 1.79 76.9 58.2
S.D. ±1.11 ±1.46 ±1.71 ±101.2 ±48.8
S.E. ±0.42 ±0.55 ±0.70 + 38.2 ±19.9
P Bed Rest = Base Value* 0.17
P Recovery = Base Value 0.12
Ambulatory Group
BEN 2.09 0.86 1.12 41.1 53.6
DEJ 2,77 1.14 1.16 41.2 41.9
PAC 4.85 0.59 0.98 12.2 20.2
QUE 1.11 0.56 1.89 50.5 170.3
Mean 2.71 0.79 1.29 36.3 71.5
S.D. ±1.58 ±0.27 ±0.41 ±16.6 ±67.3
S.E. ±0.79 ±0.14 ±0.20 8.3 ±33.7
P 16-17 Oct = Base Value 0.099
P 21-22 Oct = Base Value 0.24
P Bed Rest = Ambulatory 0.46
P Recovery = Ambulatory 0.72
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
77
Table 61. Urine epinephrine excretion rate (nmol/24 hr) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 23.5 8.1 10.7 34.5 45.5
FRE 9.8 7.1 -- 72.4 --
KEE 9.3 5.9 20.8 63.4 223.7
KUL 5.5 12.5 21.1 227.3 383.6
PAR 17.7 12.3 24.4 69.5 137.9
SCA 8.4 14.3 24.0 170.2 285.7
VAN 8.5 2.8 8.9 32.9 104.7
ZIM 11.7 1.2 14.4 10.3 123.1
Mean 11.8 8.0 17.8 85.1 186.3
S.D. ±5.9 ±4.7 ±6.4 +74.9 ±117.6
S.E. ±2.1 ±1.7 ±2.4 +26.5 ± 44.5
P Bed Rest = Base Value* 0.20
P Recovery = Base Value 0.19
Ambulatory Group
BEN 17.8 13.0 11.5 73.0 64.6
DEJ 10.8 11.1 4.7 102.8 43.5
PAC 9.2 5.4 11.0 58.7 119.6
QUE 13.3 2.4 13.9 18.0 104.5
Mean 12.8 8.0 10.3 63.1 83.1
S.D. ±3.8 ±4.9 ±3.9 +35.2 ±35.1
S.E. ±1.9 ±2.5 ±2.0 +17.6 ±17.6
P 16-17 Oct = Base Value 0.13
P 21-22 Oct = Base Value 0.33
P Bed Rest = Ambulatory 0.60
P Recovery Ambulatory 0.13
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 62. Urine norepinephrine excretion rate (nmol/24 hr) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 203 110 261 54.2 128.6
FRE 103 54 -- 52.4 --
KEE 134 106 421 79.1 314.2
KUL 134 104 189 77.6 141.0
PAR 226 88 387 38.9 171.2
SCH 126 68 229 54.0 181.7
VAN 133 36 121 27.1 91.0
ZIM 167 50 287 29.9 171.9
Mean 153 77 271 51.7 171.4
S.D. ±42 ±29 ±106 +19.6 ±70.4
S.E. ±15 ±10 + 40 ± 6.9 ±26.6
P Bed Rest = Base Value* 0.001*
P Recovery = Base Value 0.022*
Ambulatory Group
BEN 116 146 267 125.9 230.2
DEJ 90 121 106 134.4 117.8
PAC 142 68 243 47.9 171.1
QUE 112 62 180 55.4 160.7
Mean 115 99 199 90.9 170.0
S.D. ±21 ±41 ±72 . ±45.6 ±46.3
S.E. ±11 ±20 ±36 ±22.8 ±23.2
P 16-17 Oct = Base Value 0.60
P 21-22 Oct = Base Value 0.060
P Bed Rest = Ambulatory 0.057
P Recovery = Ambulatory 0.97
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 63. Urine norepinephrine/epinephrine excretion (24 hr) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 8.6 13.6 24.4 158.1 283.7
FRE 10.5 7.6 -- 72.4 --
KEE 14.4 18.0 20.2 125.0 140.3
KUL 24.4 8.3 9.0 34.0 36.9
PAR 12.8 7.2 15.9 56.3 124.2
SCH 15.0 4.8 9.5 32.0 63.3
VAN 15.6 12.9 13.6 82.7 87.2
ZIM 14.3 41.7 19.9 291.6 139.2
Mean 14.5 14.3 16.1 106.5 125.0
S.D. ±4.7 ±11.9 ±5.8 +86.5 ±80.2
S.E. ±1.7 ± 4.2 ±2.2 +30.6 ±30.3
P Bed Rest = Base Value* 0.97
P Recovery = Base Value 0.79
Ambulatory Group
BEN 6.5 11.2 23.2 172.3 356.9
DEJ 8.3 10.9 22.6 131.3 272.3
PAC 15.4 12.6 22.1 81.8 143.5
QUE 8.4 25.8 12.9 307.1 153.6
Mean 9.7 15.1 20.2 173.1 231.6
S.D. ±3.9 ±7.2 ±4.9 +96.7 ±102.0
S.E. ±2.0 ±3.6 ±2.4 +48.3 . 51.0
P 16-17 Oct = Base Value 0.29
P 21-22 Oct = Base Value 0.037*
P Bed Rest = Ambulatory 0.25
P Recovery = Ambulatory 0.086
* Value of P <0.05 indicates a statistically significant difference between
the-two-p opul-at-ions-comp ared.
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Table 64. Urine cyclic-AMP excretion rate (Umol/24 hr) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 1.91 1.05 1.59 55.0 83.2
FRE 1.17 1.40 -- 119.7 --
KEE 1.48 3.28 1.93 221.6 130.4
KUL 1.62 1.22 1.26 75.3 77.8
PAR 2.80 2.97 2.55 106.1 91.1
SCH 1.74 2.29 1.56 131.6 89.7
VAN 1.61 0.96 1.81 59.6 112.4
ZIM 2.54 1.02 1.38 40.2 54.3
Mean 1.86 1.77 1.73 101.1 91.3
S.D. ±0.55 ±0.94 ±0.43 ±58.6 ±24.5
S.E. ±0.19 ±0.33 ±0.16 +20.7 + 9.2
P Bed Rest = Base Value* 0.82
P Recovery = Base Value 0.27
Ambulatory Group
BEN 0.87 2.74 1.64 314.9 188.5
DEJ 1.40 3.01 1.32 215.0 94.3
PAC 1.82 2.01 2.34 110.4 128.6
QUE 2.13 1.89 1.82 88.7 .85.4
Mean 1.56 2.41 1.78 182.3 124.2
S.D. . ±0.55 ±0.55 ±0.43 ±104.2 ±46.7
S.E. ±0.27 ±0.27 ±0.21 + 52.1 ±23.4
P 16-17 Oct = Base Value 0.20
P 21-22 Oct = Base Value 0.44
P Bed Rest = Ambulatory 0.11
P Recovery = Ambulatory 0.15
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 65. Qualitative recapitulation of changes observed in the 63 parameters evaluated
on day 17 of bed rest in the 8 subjects of the Bed-Rest Group and the 4 sub-
jects of the Ambulatory Group during the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Bed-Rest
Bed-Rest Amb. vs Bed-Rest Amb. vs
Group Group Amb. Group Group Amb.
Body Weight - - - Plasma LDH-2 - - -
Plasma Volume + - * Plasma LDH-3 ' -
Venous Hematocrit 4 + - Plasma LDH-4 - - -
Blood Hemoglobin - - - Plasma LDH-5 - - -
Body Water - + - Plasma GOT + + -
Extracellular Water - t * Plasma GPT - - -
Intracellular Water - + - Plasma ALP t + -
Body Potassium + - *
Plasma Potassium - - * Urine Volume 4 - -
Plasma Sodium + - Urine Sp Gr - - -
Plasma Calcium - - - Urine Osm Act 4 - -
Plasma Magnesium t + - Urine pH 4 - -
Plasma Chloride 1 t - Urine Chloride + - *
Plasma Protein - - - Urine Sodium + - -
Plasma Albumin + - - Urine Potassium + - -
Plasma Globulins + - - Urine Na/K - - -
Plasma Fibrinogen + - Urine Magnesium - - -
A/G Ratio + - - Urine Calcium - - -
Circ Plasma Protein + - * Urine Phosphate - - -
Circ Albumin + - * Urine Total N + - -
Circ Globulins - - - Urine Ammonia - - -
Circ Fibrinogen + + * Urine Urea + + -
Plasma a-l-Globulin - - - Urine Creatinine + - -
Plasma a-2-Globulin - - - Urine Creatine - - -
Plasma 8-Globulin + - - Urine Hydroxyproline + - -
Plasma y-Globulin - - - Urine Glucose + 4 -
Circ a-l-Globulin - - - Urine Citrate - - -
Circ.a-2-Globulin - - - Urine 17-OHCS - - -
Circ a-Globulin - - - Urine Epinephrine - - -
Circ y-Globulin - - - Urine Norepinephrine + - -
Plasma Total LDH + 4 - Urine NE/E - - -
Plasma LDH-l . + + - Urine Cyclic-AMP - - -
+ Mean value significantly lower CP <.05) on day 17 of bed rest than 7 days before.
+ Mean value significantly higher (P <.05) on day 17 of bed rest than 7 days before.
* Mean change on day 17 of bed rest for Bed-Rest Group significantly different
(P <.05) from Ambulatory Group.
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Table 66. Urine osmotic activity (mosm/mol creatinine) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest ... Recovery 23-24 Sep 23-24 Sep
CAP 72.1 39.0 40.2 54.1 55.8
FRE 65.9 43.1 -- 65.4 --
KEE 88.7 85.3 93.4 96.2 105.3
KUL 77.6 76.5 89.3 98.6 115.1
PAR 93.4 62.8 82.8 67.2 88.7
SCH 97.1 57.1 70.1 58.8 72.2
VAN 41.5 62.2 63.9 149.9 202.2
ZIM 97.0 68.2 88.7 70.3 91.4
Mean 79.2 61.8 78.3 82.6 104.4
S.D. ±19.2 ±15.6 ±18.4 ±31.7 ±47.4
S.E. + 6.8 ± 5.5 - 6.9 ±11.2 ±17.9
P Bed Rest = Base Value* 0.049*
P Recovery = Base Value 0.79
Ambulatory Group
BEN 87.0 87.4 89.1 100.5 102.4
DEJ 104.3 83.6 91.5 80.2 87.7
PAC 102.6 76.7 72.6 74.8 70.8
QUE 104.2 69.0 104.6 66.2 100.4
Mean 99.5 79.2 89.5 80.4 90.3
S.D. + 8.4 ± 8.1 ±13.1 ±14.6 ±14.6
S.E. - 4.2 ± 4.1 - 6.6 ± 7.3 + 7.3
P 16-17 Oct = Base Value 0.074
P 21-22 Oct = Base Value 0.27
P Bed Rest = Ambulatory 0.90
P Recovery = Ambulatory 0.59
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 67. Urine chloride excretion (mol/mol creatinine) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 15.8 5.6 8.0 35.4 50.6
FRE 17.6 6.9 -- 39.2 --
KEE 22.7 13.0 15.8 57.3 69.6
KUL 23.0 12.9 21.0 56.1 91.3
PAR 23.6 11.5 13.8 48.7 58.5
SCH 28.6 10.8 18.6 37.8 65.0
VAN 14.6 11.2 21.2 76.7 145.2
ZIM 21.9 10.2 21.2 46.6 96.8
Mean 21.0 10.3 17.1 49.7 82.4
S.D. ±4.7 ±2.7 ±4.9 ±13.6 ±32.4
S.E. ±1.6 ±0.9 ±1.9 + 4.8 ±12.2
P Bed Rest = Base Value*' <0.001*
P Recovery = Base Value 0.10
Ambulatory Group
BEN 20.0 18.2 19.6 91.0 98.0
DEJ 23.9 13.7 26.3 57.3 110.0
PAC 15.6 15.7 15.4 100.6 . 98.7
QUE 29.7 12.7 28.3 42.8 95.3
Mean 22.3 15.1 22.4 72.9 100.5
S.D. ±6.0 ±2.4 ±6.0 ±27.4 ±6.5
S.E. ±3.0 ±1.2 ±3.0 ±13.7 +3.3
P 16-17 Oct = Base Value 0.17
P 21-22 Oct = .Base Value 0.91
P Bed Rest = Ambulatory 0.072
P Recovery = Ambulatory 0.31
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 68. Urine sodium excretion (mol/mol creatinine) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep . 23-24 Sep
CAP 15.4 5.2 7.6 33.8 49.4
FRE 18.4 9.1 -- 49.5 --
KEE 22.1 15.7 16.5 71.0 74.7
KUL 24.4 19.8 21.7 81.1 88.9
PAR 25.3 17.0 16.4 67.2 64.8
SCH 35.0 13.9 21.0 39.7 60.0
VAN 14.2 13.1 24.4 92.3 171.8
ZIM 21.1 12.1 24.7 57.3 117.1
Mean 22.0 13.2 18.9 61.5 89.5
S.D. ±6.6 ±4.6 ±6.0 +20.2 ±42.5
S.E. ±2.3 ±1.6 ±2.3 + 7.1 ±16.1
P Bed Rest = Base Value* 0.004*
P Recovery = Base Value 0.29
Ambulatory Group
BEN 18.7 20.8 20.3 111.2 108.6.
DEJ 26.5 13.3 26.3 50.2 , 99.2
PAC 13.7 21.3 17.5 155.5 82.2
QUE 33.1 16.3 31.0 49.2 93.7
Mean 23.0 17.9 23.8 91.5 95.9
S.D. ±8.5 ±3.8 ±6.1 +51.6 ±11.0
S.E. ±4.3 ±1.9 ±3.0 +25.8 + 5.5
P 16-17 Oct = Base Value 0.45
P 21-22 Oct = Base Value 0.58
P Bed Rest = Ambulatory 0.17
P Recovery = Ambulatory 0.78
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 69. Urine potassium excretion (mol/mol creatinine) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 4.47 3.27 3.07 73.1 68.7
FRE 3.80 2.35 -- 61.8 --
KEE 7.22 6.36 10.63 88.1 147.2
KUL 8.19 5.65 4.82 69.0 58.9
PAR 7.75 6.24 6.07 80.5 78.3
SCH 7.93 4.59 4.48 57.9 56.5
VAN 4.92 3.86 3.57 78.5 72.6
ZIM 7.55 3.70 5.65 49.0 74.8
Mean 6.48 4.50 5.47 69.7 79.6
S.D. ±1.77 ±1.46 ±2.51 ±13.0 ±30.9
S.E. ±0.63 ±0.52 ±0.95 ± 4.6 ±11.7
P Bed Rest = Base Value* 0.002*
P Recovery = Base Value 0.16
Ambulatory Group
BEN 5.86 5.87 9.95 100.2 169.8
DEJ 5.85 6.38 5.29 109.1 90.4
PAC 5.18 4.50 4.20 86.9 81.1
QUE 7.44 6.00 4.98 80.6 66.9
Mean 6.08 5.69 6.11 94.2 102.1
S.D. ±0.96 ±0.82 ±2.60 ±12.9 ±46.2
S.E. ±0.48 ±0.41 ±1.30 ± 6.4 ±23.1
P 16-17 Oct = Base Value 0.42
P 21-22 Oct = Base Value 0.99
P Bed Rest = Ambulatory 0.011*
P Recovery = Ambulatory 0.35
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 70. Urine magnesium excretion (mmol/mol creatinine) for the subjects of
the 1973 NASA/Ames Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 250 275 141 110.0 56.4
FRE 307 441 -- 143.6 --
KEE 299 677 330 226.4 110.4
KUL 400 945 359 236.3 89.8
PAR 395 592 470 149.9 119.0
SCH 344 636 283 184.9 82.3
VAN 267 343 369 128.5 138.2
ZIM 424 457 413 107.8 97.4
Mean 336 . 546 338 160.9 99.1
S.D. ±65 ±214 ±105 ±49.9 ±26.6
S.E. ±23 ± 76 ± 40 ±17.6 ±10.1
P Bed Rest = Base Value* 0.014*
P Recovery = Base Value 0.95
Ambulatory Group
BEN 411 683 315 166.2 76.6
DEJ 280 458 342 163.6 122.1
PAC 253 526 333 207.9 131.6
QUE 695 620 525 89.2 75.5
Mean 410 572 379 156.7 101.5
S.D. ±202 ±100 ±98 ±49.4 ±29.6
S.E. ±101 ± 50 ±49 ±24.7 ±14.8
P 16-17 Oct = Base Value 0.14
p 21-22 Oct = Base Value 0.65
P Bed Rest = Ambulatory 0.89
P Recovery = Ambulatory 0.89
* Value of P <0.05 indicates a statistically significant difference between the
two populations compared.
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Table 71. Urine calcium excretion rate (mmol/mol creatinine) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 372 357 264 96.0 71.0
FRE 319 611 -- 191.5 --
KEE 559 741 361 132.6 64.6
KUL 550 798 618 145.1 112.4
PAR 520 722 597 138.8 114.8
SCH 548 626 471 114.2 85.9
VAN 276 273 431 98.9 156.2
ZIM 544 493 557 90.6 102.4
Mean 461 578 471 126.0 101.0
S.D. ±118 ±188 ±130 +33.6 ±31.2
S.E. ± 42 _ 67 + 49 ±11.9 ±11.8
P Bed Rest = Base Value* 0.040*
P Recovery = Base Value 0.84
Ambulatory Group
BEN 457 619 416 135.4 91.0
DEJ 461 548 533 118.9 115.6
PAC 503 567 434 112.7 86.3
QUE 452 451 517 99.8 114.4
Mean 468 546 475 116.7 101.8
S.D. ±23 ±70 ±59 ±14.8 ±15.3
S.E. ±12 ±35 ±29 ± 7.4 + 7.7
P 16-17 Oct = Base Value 0.10
P 21-22 Oct = Base Value 0.86
P Bed Rest = Ambulatory 0.62
P Recovery = Ambulatory 0.96
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 72. Urine phosphate excretion (mol/mol creatinine) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 1.65 1.80 1.46 109.1 88.5
FRE 1.94 2.80 -- 144.3 --
KEE 3.08 3.72 4.01 120.8 130.2
KUL 3.28 3.84 3.02 117.1 92.1
PAR 2.27 3.48 3.24 153.3 142.7
SCH 2.28 2.89 2.41 126.8 105.7
VAN 2.09 2.27 2.42 108.6 115.8
ZIM 2.39 2.77 3.60 115.9 150.6
Mean 2.37 2.95 2.88 124.5 117.9
S.D. ±0.55 ±0.71 ±0.86 +16.3 ±24.2
S.E. ±0.20 ±0.25 ±0.32 + 5.8 + 9.2
P Bed Rest = Base Value* 0.002*
P Recovery = Base Value 0.094
Ambulatory Group
BEN 2.56 3.75 2.64 146.5 103.1
DEJ 2.66 3.24 2.40 121.8 90.2
PAC 2.05 3.08 2.68 150.2 130.7
QUE 2.70 2.15 3.63 79.6 134.4
Mean 2.49 3.06 •2.84 124.5 114.6
S.D. ±0.30 ±0.67 ±0.54 +32.5 ±21.4
S.E. ±0.15 ±0.33 ±0.27 +16.2 ±10.7
P 16-17 Oct = Base Value 0.25
p 21-22 Oct = Base Value 0.29
P Bed Rest =Ambulatory 0.99
P Recovery = Ambulatory 0.82
* Value of P <0.05 indicates a statistically significant difference between the
two populations compared.
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Table 73. Urine total nitrogen excretion (g/mmol creatinine) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep. .. 23-24 Sep
CAP 0.86 0.62 0.50 72.1 58.1
FRE 0.73 0.62 -- 84.9 --
KEE 1.35 1.52 1.28 112.6 94.8
KUL 1.61 1.37 0.91 85.1 56.5
PAR 1.25 1.05 1.07 84.0 85.6
SCH 0.85 1.05 0.77 123.5 90.6 '
VAN 0.89 0.70 0.93 78.7 104.5
ZIM 1.26 0.77 1.15 61.1 91.3
Mean 1.10 0.96 0.94 87.8 83.1
S.D. ±0.31 ±0.34 ±0.26 ±20.6 ±18.5
S.E. ±0.11 ±0.12 ±0.10 ± 7.3 + 7.0
P Bed Rest = Base Value* 0.13
P Recovery = Base Value 0.069
Ambulatory Group
BEN 1.14 1.15 0.98 100.9 86.0
DEJ 1.33 1.47 0.81 110.5 60.9
PAC 1.15 0.72 0.87 62.6 75.7
QUE 0.88 1.58 1.50 179.5 170.5
Mean 1.13 1.23 1.04 113.4 98.3
S.D. ±0.19 ±0.39 ±0.31 ±48.7 ±49.2
S.E. .±0.09 ±0.19 ±0.16 +24.3 ±24.6
P 16-17 Oct = Base Value 0.68
P 21-22 Oct - Base Value 0.75
P Bed Rest = Ambulatory 0.22
P Recovery = Ambulatory 0.75
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
90
Table 74. Urine ammonia excretion (mol/mol creatinine) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 2.42 1.97 1.96 81.4 81.0
FRE 2.10 4.57 -- 217.6 --
KEE 3.30 4.36 3.84 .132.1 116.4
KUL 2.81 3.52 3.82 125.3 135.9
PAR 3.36 3.58 4.53 106.5 134.8
SCH 2.79 4.26 3.44 152.7 123.3
VAN 2.56 2.43 2.37 94.9 92.6
ZIM 2.34 3.01 1.81 128.6 77.4
Mean 2.71 3.46 3.11 129.9 108.8
S.D. ±0.45 ±0.94 ±1.06 ±42.0 ±24.8
S.E. ±0.16 ±0.33 ±0.40 +14.9 + 9.4
P Bed Rest = Base Value* 0.056
P Recovery = Base Value 0.28
Ambulatory Group
BEN 3.35 4.67 1.24 139.4 37.0
DEJ 2.21 3.58 2.40 162.0 108.6
PAC 4.30 2.32 3.33 54.0 77.4
QUE 2.92 3.90 2.82 133.6 96.6
Mean 3.20 3.62 2.45 122.3 79.9
S.D. ±0.87 ±0.98 ±0.89 +47.1 ±31.4
S.E. ±0.44 ±0.49 ±0.45 +23.6 ±15.7
P 16-17 Oct = Base Value 0.64
P 21-22 Oct - Base Value 0.24
P Bed Rest = Ambulatory 0.78
P Recovery = Ambulatory 0.12
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 75. Urine urea excretion (mol/mol creatinine) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 44.2 20.4 16.4 46.2 37.1
FRE 31.5 20.6 -- 65.4 --
KEE 57.5 48.1 44.6 83.7 77.6
KUL 59.5 40.3 40.0 67.7 67.2
PAR 66.2 50.1 42.4 75.7 64.0
SCH 40.2 33.9 38.7 84.3 96.3
VAN 30.6 26.1 31.3 85.3 102.3
ZIM 41.5 29.1 35.0 70.1 84.3
Mean 46.4 33.6 35.5 72.3 75.5
S.D. ±13.2 ±11.6 ±9.5 +13.1 ±22.0
S.E. ± 4.7 ± 4.1 ±3.6 + 4.6 ± 8.3
P Bed Rest = Base Value* <0.001*
P Recovery = Base Value 0.021*
Ambulatory Group
BEN 43.2 38.6 34.6 89.4 80.1
DEJ 54.5 46.3 34.6 85.0 63.5
PAC 38.8 28.4 29.9 73.2 77.1
QUE 38.7 27.4 41.4 70.8 107.0
Mean 43.8 35.2 35.1 79.6 81.9
S.D. ±7.4 ±9.0 ±4.7 ±9.0 ±18.2
S.E. ±3.7 ±4.5 ±2.4 ±4.5 ± 9.1
P 16-17 Oct = Base Value 0.010*
P 21-22 Oct = Base Value 0.16
P Bed Rest = Ambulatory 0.35
P Recovery = Ambulatory 0.64
* Value of P <0.05 indicates a statistically significant difference between the
two populations compared.
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Table 76. Urine creatine excretion (mmol/mol creatinine) for the subjects of the
1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 82 164 85 200.0 103.6
FRE 155 176 -- 113.5 --
KEE 269 349 569 129.7 211.5
KUL 349 487 217 139.5 62.2
PAR 355 216 108 60.8 30.4
SCH 311 333 203 107.1 65.3
VAN 212 502 205 236.8 96.7
ZIM 127 308 155 242.5 122.0
Mean 233 317 220 153.7 98.8
S.D. ±104 ±130 ±162 ±65.6 ±58.3
S.E. ± 37 - 46 - 61 ±23.2 ±22.0
P Bed Rest = Base Value* 0.10
P Recovery = Base Value 0.73
Ambulatory Group
BEN 169 207 73 122.5 43.2
DEJ 400 200 615 50.0 153.8
PAC 256 393 130 153.5 50.8
QUE 256 193 113 75.4 44.1
Mean 270 248 233 100.4 73.0
S.D. ±96 ±97 ±256 ±46.5 ±54.0
S.E. +48 ±48 ±128 ±23.2 ±27.0
P 16-17 Oct = Base Value 0.78
P 21-22 Oct = Base Value 0.69
P Bed Rest = Ambulatory 0.18
P Recovery Ambulatory 0.49
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
93
Table 77. Urine hydroxyproline excretion rate (mmol/mol creatinine) for the
subjects of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 32.2 33.5 19.4 104.0 60.2
FRE -- --. -- --
KEE 46.5 39.8 32.3 85.6 69.5
KUL 40.5 55.9 29.5 138.0 72.8
PAR 44.5 30.6 34.1 68.8 76.6
SCH 57.0 37.7 39.2 66.1 68.8
VAN 41.9 31.3 33.7 74.7 80.4
ZIM 38.6 29.4 30.6 76.2 79.3
Mean 43.0 36.9 31.3 87.6 72.5
S.D. ±7.7 ±9.2 ±6.1 +25.6 ±7.1
S.E. ±2.9 ±3.5 ±2.3 ± 9.7 ±2.7
P Bed Rest = Base Value* 0.20
P Recovery = Base Value <0.001*
Ambulatory Group
BEN 26.5 50.8 21.2 191.7 80.0
DEJ 41.2 30.8 6.0 74.8 14.6
PAC 36.5 22.4 19.2 61.4 52.6
QUE 9.2 27.4 32.2 297.8 350.0
Mean 28.4 32.9 19.7 156.4 124.3
S.D. ±14.2 ±12.5 ±10.7 ±110.9 ±152.8
S.E. + 7.1 ±6.2 ± 5.4 + 55.5 ± 76.4
P 16-17 Oct = Base Value 0.68
P 21-22 Oct = Base Value 0.53
P Bed Rest = Ambulatory 0.14
P Recovery = Ambulatory 0.37
* Value of P <0.05 indicates a statistically significant difference between the
two populations compared.
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Table 78. Urine glucose excretion (mmol/mol creatinine) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 38.9 11.1 23.1 28.5 59.4
FRE 60.7 27.6 -- 45.5 --
KEE 55.6 54.3 -- 97.7 --
KUL 65.9 44.2 74.7 67.1 113.4
PAR 57.5 60.5 104.1 105.2 181.0
SCH 112.0 54.9 121.1 49.0 108.1
VAN 35.5 39.2 41.2 110.4 116.1
ZIM 37.6 25.6 45.8 68.1 121.8
Mean 58.0 39.7 68.3 71.4 116.6
S.D. ±24.7 ±17.2 ±38.5 +30.2 ±38.8
S.E. ± 8.7 _ 6.1 ±15.7 +10.7 ±15.8
P Bed Rest = Base Value* 0.043*
P Recovery = Base Value 0.26
Ambulatory Group
BEN 52.7 44.9 42.4 85.2 80.5
DEJ 49.0 34.8 60.0 71.0 122.4
PAC 43.8 30.9 32.8 70.5 74.9
QUE 65.3 37.2 57.3 57.0 87.7
Mean 52.7 37.0 48.1 70.9 91.4
S.D. ±9.2 ±5.9 ±12.8 ±11.5 ±21.3
S.E. ±4.6 ±3.0 ± 6.4 ± 5.8 +10.7
P 16-17 Oct = Base Value 0.036*
P 21-22 Oct = Base Value 0.45
P Bed Rest = Ambulatory 0.98
P Recovery = Ambulatory 0.27
* Value of P <0.05 indicates a statistically significant difference between the
two populations compared.
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Table 79. Urine citrate excretion (mmol/mol creatinine) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 104 130 128. 125.0 123.1
FRE 281 263 -- 93.6 --
KEE 226 419 601 185.4 265.9
KUL 208 341 485 163.9 233.2
PAR 416 736 690 176.9 165.9
SCH 425 667 375 156.9 88.2
VAN 226 428 521 189.4 230.5
ZIM 278 415 402 149.3 144.6
Mean 271 425 457 155.1 178.8
S.D. ±107 ±198 ±182 ±32.5 ±65.7
S.E. + 38 ± 70 ± 69 +.11.5 ±24.8
P Bed Rest = Base Value* 0.006*
P Recovery = Base Value 0.020*
Ambulatory Group
BEN 287 411 702 143.2 244.6
DEJ 310 365 565 117.7 182.3
PAC 258 601 339 - 232.9 131.4
QUE 574 736 518 128.2 90.2
Mean 357 528 531 155.5 162.1
S.D. ±146 ±172 ±150 +52.7 ±66.6
S.E. ± 73 ± 86 ± 75 +26.3 ±33.3
P 16-17 Oct = Base Value 0.069
P 21-22 Oct = Base Value 0.19
P Bed Rest = Ambulatory 0.99
P Recovery = Ambulatory 0.70
* Value of P <0.05 indicates a statistically significant difference between the
two populations compared.
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Table 80. Urine 17-OH corticosteroid excretion (Pmol/mol creatinine) for the
subjects of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery .23-24 Sep . 23-24 Sep
CAP 187 124 206 66.3 110.2
FRE 177 857 -- 484.2 --
KEE 377 273 891 72.4 236.3
KUL 335 171 144 51.0 43.0
PAR 445 313 151 70.3 33.9
SCH -- -- -- -- --
VAN 429 187 42 43.6 9.8
ZIM 209 47 152 22.5 72.7
Mean 308 282 264 115.8 .84.3
S.D. ±116 ±269 ±312 ±163.4 ±82.1
S.E. + 44 ±102 ±127 + 61.8 ±33.5
P Bed Rest = Base Value* 0.83
P Recovery = Base Value 0.64
Ambulatory Group
BEN 230 100 123 43.5 53.5
DEJ 275 125 242 45.5 88.0
PAC 524 87 91 16.6 17.4
QUE 138 113 213 81.9 154.3
Mean . 292 106 167 46.9 78.3
S.D. ±165 ±16 ±72 ±26.8 ±58.3
S.E. ± 82 _ 8 ±36 ±13.4 ±29.1
P 16-17 Oct = Base Value 0.13
P 21-22 Oct = Base Value 0.34
P Bed Rest = Ambulatory 0.43
P Recovery = Ambulatory 0.90
* Value of P <0.05 indicates a statistically significant difference between the
two populations compared.
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Table 81. Urine epinephrine excretion (Cpmol/mol creatinine) for the subjects
of the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest . Recovery 23-24 Sep 23-24 Sep
CAP 2.28 1.07 1.78 46.9 78.1
FRE 1.13 1.31 -- 115.9 --
KEE 1.00 0.71 3.61 71.0 361.0
KUL 0.52 1.68 3.14 323.1 603.8
PAR 1.73 1.66 2.19 96.0 126.6
SCH 1.02 1.66 3.10 162.7 186.7
VAN 1.00 0.56 1.57 56.0 157.0
ZIM 1.14 0.28 1.51 24.6 132.5
Mean 1.23 1.12 2.41 112.0 235.1
S.D. ±0.54 ±0.55 ±0.85 +95.7 ±185.8
S.E. ±0.19 ±0.19 ±0.32 +33.8 _ 70.2
P Bed Rest = Base Value* 0.70
P Recovery = Base Value 0.047*
Ambulatory Group
BEN 1.96 1.51 1.26 77.0 64.3
DEJ 1.07 1.22 .0.98 114.0 91.6
PAC 0.99 0.79 1.02 79.8 103.0
QUE 1.65 0.48 1.57 29.1 95.2
Mean 1.42 1.00 1.21 75.0 88.5
S.D. ±0.47 ±0.46 ±0.27 +34.9 ±16.8
S.E. ±0,23 ±0.23 ±0.14 +17.5 ± 8.4
P 16-17 Oct = Base Value 0.23
p 21-22 Oct = Base Value 0.29
P Bed Rest = Ambulitory 0.48
P Recovery = Ambulatory 0.16
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 82. Urine norepinephrine excretion (.Ijmol/mol creatinine for the subjects
of the 1973 NASA/Ames Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24.Sep ... 23-24 Sep
CAP 19.7 14.6 43.4 74.1 .220.3
FRE 11.9 10.0 -- 84.0 --
KEE 14.4 12.8 73.1 88.9 507.6
KUL 12.8 14.0 28.1 109.4 219.5
PAR 22.1 11.9 34.7 53.8 157.0
SCH 15.3 7.9 29.6 51.6 193.5
VAN 15.6 7.2 21.4 46.2 137 .2
ZIM 16.3 11.8 30.1 72.4 184.7
Mean 16.0 11.3 37.2 72.6 231.4
S.D. 13.4 ±2.7 .±17.2 ±21.5 ±125.6
S.E. ±1.2 ±1.0 ± 6.5 ± 7.6 ± 47.5
P Bed Rest = Base Value* 0.010*
P Recovery = Base Value 0.021'
Ambulatory Group
BEN 12.7 17.0 29.3 133.9 230.7
DEJ 8.9 13.3 22.1 149.4 248.3
PAC 15.3 10.0 22.5 65.4 147.1
QUE 13.9 12.5 20.3 89.9 146.0
Mean 12.7 13.2 23.6 109.7 193.0
S.D. ± 2.7 ±2.9 ±4.0 +38.8 ±54.1
S.E. ±1.4 ±1.4 ±21.0 +19.4 ±27.1
P 16-17 Oct = Base Value 0.85
P 21-22 Oct = Base Value 0.021*
P Bed Rest = Ambulatory 0.055
P Recovery = Ambulatory 0.58
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
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Table 83. Urine cyclic-AMP excretion (pmol/mol creatinine) for the subjects of
the 1973 NASA/Ames Female Bed-Rest Study.
Bed-Rest Group
23-24 Sep 16-17 Oct 21-22 Oct
Day -7 Day 17 Day 6 16-17 Oct 21-22 Oct
Subject Base Value Bed Rest Recovery 23-24 Sep 23-24 Sep
CAP 185 139 264 75.1 142.7
FRE .135 259 -- 191.9 --
KEE 159 395 335 248.4 210.7
KUL .154 164 188 106.5 122.1
PAR 274 400 228 146.0 83.2
SCH 211 266 202 126.1 95.7
VAN 189 191 320 101.1 169.3
ZIM 247 242 145 98.0 58.7
Mean 194. 257 240 136.6 126.1
S.D. ±48 ±98 ±70 ± 57.6 ±52.6
S.E. 217 ±35 ±26 +20.4 ±19.9
P Bed Rest = Base Value* 0.098
P Recovery = Base Value 0.35
Ambulatory Group
BEN 96 319 180 332.3 187.5
DEJ 139 331 275 238.1 . 197.8
PAC . 197 295 216 149.7 109.6
QUE 264 380 205 143.9 77.7
Mean 174 331 219 216.0 143.2
S.D. ±73 ±36 ±40 +88.7 ±58.8
S.E. ±36 ±18 ±20 +44.4 ±29.4
P 16-17 Oct = Base Value 0.013*
P 21-22 Oct = Base Value 0.36
P Bed Rest = Ambulatory 0.087
P Recovery = Ambulatory 0.63
* Value of P <0.05 indicates a statistically significant difference between
the two populations compared.
1lQ
Table 84. Qualitative recapitulation of the changes observed in
24 urine parameters evaluated during the 1973 NASA/Ames
Female Bed-Rest Study, and computed where appropriate
on the basis of excretion per unit of urinary creatinine.
Bed-Rest
Bed-Rest Ambulatory vs
Group Group Ambulatory
t Urine Volume + -
t Urine Sp Gr - -
Urine Osm Act + -
t Urine pH + 
-
Urine Chlpride + -
Urine Sodium + -
Urine Potassium + -
t Urine Na/K - -
Urine Magnesium t -
Urine Calcium 
-
Urine Phosphate + -
Urine Total N - -
Urine Ammonia - -
Urine Urea + +
t Urine Creatinine + 
-
Urine Creatine 
-
Urine Hydroxyproline 
-
Urine Glucose + +
SUrine Citrate + 
-
Urine 17-OHCS 
-
-
Urine Epinephrine 
-
-
Urine Norepinephrine' + -
t Urine NE/E 
-
Urine Cyclic-AMP 
- +
t Not recomputed on the basis of creatinine.
+ Mean value significantly lower (P <.05) on day 17 of bed rest
than 7 days before.
+ Mean value significantly higher (P <.05) on day 17 of bed rest
than 7 days before.
* Mean change on day 17 of bed rest for Bed-Rest Group signifi-
cantly different (P <.05) from Ambulatory Group.
